Document:

Exhibit 10.1

 

SCHEDULE
5 – FORM OF WARRANT AGREEMENT

 

WARRANT
AGENCY AGREEMENT

 

THIS
WARRANT AGENCY AGREEMENT (this “Agreement”) dated as of [●] [●], 2021, between WIZE PHARMA,
INC., a Delaware corporation, with offices at 24 Hanagar Street, Hod Hasharon, Israel (the “Company”),
and [●], a [●] corporation, with offices at [●], as warrant agent (the “Agent”).

 

WHEREAS,
on December [●], 2020, the Company and Cosmos Capital Limited (ACN 636 458 912) (the “Target”) entered
into a Bid Implementation Agreement (the “BIA”), whereby, among other things, the Company agreed to commence
an offer (the “Offer”) to purchase all of the outstanding ordinary shares (the “Cosmos Shares”)
of the Target;

 

WHEREAS,
the Company plans to consummate the Offer on or about the date hereof;

 

WHEREAS,
as contemplated in the BIA and the Offer, the Company has determined to issue (to the shareholders of Target accepting the Offer)
(i) an aggregate of up to [●] shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”) and (ii) warrants (the “Warrants”) to purchase an aggregate of up to [●] shares of
Common Stock, with each such Warrant evidencing the right of the holder thereof to acquire one share of Common Stock (each, a
“Warrant Share”) if and to the extent the holder thereof has satisfied the Milestone (as defined below);

 

  WHEREAS,
the Company desires the Agent to act on behalf of the Company, and the Agent is willing to so act, in connection with the issuance,
registration, transfer, exchange, redemption and exercise of the Warrants; and

 

WHEREAS,
the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Agent, and the holders of the Warrants;

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment
of Agent

 

The
Company hereby appoints the Agent to act as agent for the Company for the Warrants, and the Agent hereby accepts such appointment
and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

 

2. Warrants

 

2.1  Form
of Warrant.  Each Warrant shall be issued in registered (book entry) form only, shall be in substantially the form
of Exhibit A hereto, the provisions of which are incorporated herein and shall be signed by, or bear the facsimile or scanned
PDF signature of, the Chief Executive Officer or Chief Financial Officer of the Company and shall bear the Company’s printed
name.  In the event the person whose facsimile or scanned PDF signature has been placed upon any Warrant shall have
ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the
same effect as if he or she had not ceased to be such at the date of issuance.

 

     

     

    

 

2.2  Effect
of Countersignature.  Unless and until countersigned by the Agent pursuant to this Agreement, a Warrant shall be
invalid and of no effect and may not be exercised by the holder thereof.

 

2.3  Registration.

 

  2.3.1  Warrant
Register.  The Agent shall maintain books (the “Warrant Register”) for the registration of original
issuance and the registration of Permitted Transfers of the Warrants, which will be reflected on statements issued by the Agent
from time to time to the holders thereof reflecting their aforesaid book entry position (the “Warrant Statements”).  Upon
the initial issuance of the Warrants, the Agent shall issue and register the Warrants in the names of the respective holders thereof
in such denominations and otherwise in accordance with instructions delivered to the Agent by the Company, which shall be by way
of the Company providing a list of the shareholders of Target entitled to receive the Warrants, substantially in the form of Exhibit
B hereto (the “Holders”). 

 

2.3.2  Registered
Holder.  Prior to due presentment for registration of transfer of any Warrant (only if permitted hereunder), the
Company and the Agent may deem and treat the Holder in whose name such Warrant shall be registered upon the Warrant Register (“registered
holder”), as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of
ownership or other writing made by anyone other than the Company or the Agent), for the purpose of any exercise or entitlement
thereof, and for all other purposes, and neither the Company nor the Agent shall be affected by any notice to the contrary.

 

2.4  Legends;
Restricted Securities. Unless and until, and for so long as, the Warrants or the Warrant Shares are not registered under the
Securities Act, each certificate or book-entry position statement, as applicable, representing such securities shall bear a legend
substantially similar to the following:

 

“THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.

 

IN
ADDITION, THIS SECURITY IS NOT TRANSFERABLE EXCEPT TO THE EXTENT PERMITTED UNDER THE TERMS OF THE WARRANT AGENCY AGREEMENT.”

 

The
Agent is required to refuse to register any transfer of the Warrant or the Common Stock underlying the Warrant (i) not made in
accordance with the provisions of Regulation S, pursuant to the Securities Act or pursuant to an available exemption from registration
and (ii) not expressly permitted under this Agreement.

 

    - 2 -

     

    

 

3. Terms
of Warrants

 

3.1  Issuance
of Warrant Shares; Milestone.  

 

3.1.1 Issuance.
Each Warrant shall, when countersigned by the Agent, entitle the registered holder thereof, subject to the provisions of such
Warrant and of this Agreement, to purchase and receive from the Company the number of Warrant Shares stated therein, for no additional
consideration and without the need to exercise the Warrant, if, and only if, the Company advises the Agent that the Holder has
satisfied the Milestone, including how many Warrant Shares should be issued to the Holder (the “Milestone Notice”),
in which case, the Agent shall issue the number of Warrant Shares set forth in the Milestone Notice to the Holders set forth in
the Milestone Notice (the “Milestone Holders”). A Warrant may not be exercised, and no Warrant Shares will
be issued hereunder, unless and until the Company has delivered the Milestone Notice to the Agent in accordance with this Agreement.

 

3.1.2 Milestone.
Solely as between the Holders and the Company, it is hereby agreed as follows: (i) a Holder who satisfied the Milestone as of
the Milestone Date shall be entitled to be identified as a Milestone Holder in the Milestone Notice delivered by the Company to
the Agent, (ii) in order to determine whether a Holder satisfied the Milestone as of the Milestone Date and should be identified
as a Milestone Holder, including how many Warrant Shares should be issued thereto, the Company may rely solely on the registrar
books of the Company’s transfer agent, but, if the Company so wishes, in its sole discretion, it may also seek from the
Holder or other persons additional information, (iii) the Company’s determination under clause (ii) shall be final and conclusive
as long as it was made by the Board in good faith, and (iv) the Company shall deliver a Milestone Notice to the Agent no later
than 14 days following the Milestone Date.

 

3.2  Duration
of Warrants.   Each Warrant (i) held by a Holder who is not a Milestone Holder, as set forth in the Milestone Notice,
shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease upon delivery
of such Milestone Notice, and (ii) held by a Holder who is a Milestone Holder, as set forth in the Milestone Notice, shall become
void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease upon delivery of such Milestone
Notice, except for the right of such Milestone Holder to receive the Warrant Shares in accordance with the Milestone Notice.  

 

3.3  Issuance.

 

3.3.1 Issuance
of Certificates.  As soon as practicable after the delivery of the Milestone Notice, the Agent shall issue to each
of the Milestone Holders a certificate or certificates for the number of full shares of Common Stock to which he is entitled,
registered in such name or names as may be directed by him, her or it (or, if directed by the Company, such shares of Common Stock
will initially be issued in book-entry form, registered on the books and records of the registrar and transfer agent therefor
in such name or names as may be directed by such holder).  Warrants may not be exercised by, or securities issued to,
any registered holder in any state in which such exercise would be unlawful.   

 

3.3.2  Valid
Issuance.  All Warrant Shares issued in conformity with this Agreement shall be validly issued, fully paid and nonassessable. 

 

    - 3 -

     

    

 

3.3.3  Date
of Issuance.  Each person in whose name any such certificate (or statement for book-entry position) for Warrant
Shares is issued shall for all purposes be deemed to have become the holder of record of such shares on the date on which the
Milestone Notice has been delivered, irrespective of the date of delivery of such notice, except that, if the date of such notice
is a date when the share transfer books of the Company are closed, such person shall be deemed to have become the holder of such
shares at the close of business on the next succeeding date on which the share transfer books are open.

 

4. Adjustments

 

4.1  Stock
Dividends and Splits.  If after the date hereof, and subject to the provisions of Section 4.5 below, the number
of outstanding shares of Common Stock is increased by a share dividend payable in shares of Common Stock, or by a subdivision
of the shares of Common Stock, or other similar event, then, on the effective date of such share dividend, subdivision or similar
event, the number of Warrant Shares issuable hereunder shall be increased in proportion to such increase in outstanding shares
of Common Stock.

 

4.2  Aggregation
and Reverse Split of Shares.  If after the date hereof, and subject to the provisions of Section 4.5, the number
of outstanding shares of Common Stock is decreased by a consolidation, amalgamation, merger, combination, reverse stock split
or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination,
reverse stock split, reclassification or similar event, the number of Warrant Shares issuable hereunder shall be decreased in
proportion to such decrease in outstanding shares of Common Stock. 

 

4.3  Replacement
of Securities upon Reorganization, etc.  In case of any reclassification or reorganization of the outstanding shares
of Common Stock (other than a change covered by Section 4.1 or 4.2 hereof or that solely affects the par value of such shares
of Common Stock), or in the case of any consolidation, amalgamation, merger or combination of the Company with or into another
corporation (other than a consolidation or merger in which the Company is the continuing corporation and that does not result
in any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance
to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety
in connection with which the Company is dissolved, the registered holders shall thereafter have the right, and only the right,
to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares
of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind
and amount of shares or other securities or property (including cash) receivable upon such reclassification, reorganization, consolidation,
amalgamation, merger or combination, or upon a dissolution following any such sale or transfer, that the Board of Directors of
the Company (the “Board”) determines in good faith that the Warrant holder would have received if such Warrant
holder had been entitled to receive the Warrant Shares immediately prior to such event; and if any reclassification also results
in a change in shares of Common Stock covered by Section 4.1 or 4.2, then such adjustment shall be made pursuant to Sections 4.1,
4.2, and this Section 4.3.  The provisions of this Section 4.3 shall similarly apply to successive reclassifications,
reorganizations, mergers or consolidations, sales or other transfers.  

 

    - 4 -

     

    

 

4.4  Notices
of Changes in Warrant.  Upon every adjustment in accordance with Section 4.1, 4.2 or 4.3, the Company shall give
written notice thereof to the Agent, which notice shall state the adjustment and the increase or decrease, if any, in the number
of shares purchasable hereunder, setting forth in reasonable detail the method of calculation and the facts upon which such calculation
is based.  Upon the occurrence of any event specified in Sections 4.1, 4.2, or 4.3, then, in any such event, the Company
shall cause the Agent to give written notice to each registered holder, at the last address set forth for such holder in the warrant
register, of the record date or the effective date of the event.  Failure to give such notice, or any defect therein,
shall not affect the legality or validity of such event. 

 

4.5  No
Fractional Shares.  Notwithstanding any provision contained in this Agreement to the contrary, the Company shall
not issue fractional Warrant Shares.  If, by reason of any adjustment made pursuant to this Section 4, the holder of
any Warrant would be entitled to receive a fractional interest in a share, the Company shall round down to the nearest whole number
the number of the shares of Common Stock to be issued to the registered holder. 

 

4.6  Form
of Warrant.  The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants
issued after such adjustment may state the same number of shares as is stated in the Warrants initially issued pursuant to this
Agreement.  However, the Company may at any time, in its sole discretion, make any change in the form of Warrant that
the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned,
whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.  

 

5.Transfer
and Exchange of Warrants 

 

5.1  Registration
of Transfer.  Subject to Section 5.6 hereof, the Agent shall register the transfer, from time to time, of any outstanding
Warrant upon the Warrant Register, upon receipt of a transfer form for such Warrant, substantially in the form of Exhibit C,
properly completed with signatures properly guaranteed and accompanied by appropriate instructions for transfer.  Upon
any such transfer, a new Warrant Statement representing an equal aggregate number of Warrants shall be issued to the transferee.  The
Warrants so cancelled shall be clearly marked “cancelled” or bear a similar statement to that effect in the Warrant
Register and delivered by the Agent to the Company from time to time upon request. 

 

5.2  Procedure
for Surrender of Warrants.  Warrants may be surrendered to the Agent, together with a written request for exchange
or transfer, and thereupon the Agent shall issue in exchange therefor one or more new Warrants as requested by the registered
holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event
that a Warrant surrendered for transfer bears a restrictive legend, the Agent shall not cancel such Warrant and issue new Warrants
in exchange therefor until the Agent has received an opinion of counsel for the Company stating that such transfer may be made
and indicating whether the new Warrants must also bear a restrictive legend. 

 

5.3  Fractional
Warrants.  The Agent shall not be required to effect any registration of transfer or exchange which will result
in the issuance of a certificate for a fraction of a Warrant. 

 

5.4  Service
Charges.  No service charge shall be made for any exchange or registration of transfer of Warrants.  

 

5.5  Warrant
Execution and Countersignature.  The Agent is hereby authorized to countersign and to deliver, in accordance with
the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company,
whenever required by the Agent, will supply the Agent with Warrants duly executed on behalf of the Company for such purpose. 

 

    - 5 -

     

    

 

5.6 Non
Transferable. Notwithstanding anything to the contrary hereunder, the Warrants shall not be sold, assigned, transferred, pledged,
encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. Any
attempted sale, assignment, transfer, pledge, encumbrance or disposition of any Warrant or any right or interest therein, in whole
or in part, in violation of this Section 5.6 shall be void ab initio and of no effect. The Warrants will not be listed
on any quotation system or traded on any securities exchange.

 

6.Other
Provisions Relating to Rights of Holders of Warrants 

 

6.1  No
Rights as Shareholder.  A Warrant does not entitle the registered holder thereof to any of the rights of a stockholder
of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive
rights to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of
directors of the Company or any other matter. 

 

6.2  Lost,
Stolen, Mutilated, or Destroyed Warrants.  If any Warrant is lost, stolen, mutilated, or destroyed, the Company
and the Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case
of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant
so lost, stolen, mutilated, or destroyed.  Any such new Warrant shall constitute a substitute contractual obligation
of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by
anyone. 

 

6.3  Reservation
of Common Stock.  The Company shall at all times reserve and keep available a number of its authorized but unissued
shares of Common Stock (or out of shares held by the Company in treasury) that will be sufficient to permit the exercise in full
of all outstanding Warrants issued pursuant to this Agreement. 

 

7.Concerning
the Agent and Other Matters 

 

7.1  Payment
of Taxes.  The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company
or the Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of Warrants, but the Company shall
not be obligated to pay any transfer taxes in respect of the Warrants or such shares. 

 

7.2  Resignation,
Consolidation, or Merger of Agent.

 

  7.2.1  Appointment
of Successor Agent.  The Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company.  The
Company may terminate this Agreement and discharge the Agent, or any successor to it hereafter appointed, after giving sixty (60)
days’ notice in writing to the Agent.  If the office of the Agent becomes vacant by resignation or incapacity
to act or otherwise, the Company shall appoint in writing a successor Agent in place of the Agent.  If the Company shall
fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or
incapacity by the Agent or by the holder of a Warrant (who shall, with such notice, submit its Warrant for inspection by the Company),
then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment
of a successor Agent at the Company’s cost.  Any successor Agent, whether appointed by the Company or by such
court, shall be a corporation or other business entity organized and existing under the laws of the State of New York, in good
standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws
to exercise corporate trust powers and subject to supervision or examination by federal or state authority.  After appointment,
any successor Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor
Agent with like effect as if originally named as Agent hereunder, without any further act or deed; but if for any reason it becomes
necessary or appropriate, the predecessor Agent shall execute and deliver, at the expense of the Company, an instrument transferring
to such successor Agent all the authority, powers, and rights of such predecessor Agent hereunder; and upon request of any successor
Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually
vesting in and confirming to such successor Agent all such authority, powers, rights, immunities, duties, and obligations. 

 

    - 6 -

     

    

 

7.2.2  Notice
of Successor Agent.  In the event a successor Agent shall be appointed, the Company shall give notice thereof to
the predecessor Agent and the transfer agent for the Warrant Shares not later than the effective date of any such appointment. 

 

7.2.3  Merger
or Consolidation of Agent.  Any corporation into which the Agent may be merged or with which it may be consolidated
or any corporation or other business entity resulting from any merger or consolidation to which the Agent shall be a party shall
be the successor Agent under this Agreement without any further act, provided that such business entity (i) would be eligible
for appointment as successor to the Agent under the provisions of Section 7.2.1 above or (ii) is a wholly owned subsidiary of
the Agent. 

 

7.3  Fees
and Expenses of Agent. 

 

7.3.1  Remuneration.  The
Company agrees to pay the Agent the fees and expenses set forth in Exhibit D hereto. 

 

7.3.2  Further
Assurances.  The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the
Agent for the carrying out or performing of the provisions of this Agreement. 

 

7.4  Liability
of Agent. 

 

7.4.1  Reliance
on Company Statement.  Whenever in the performance of its duties under this Agreement, the Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a statement signed by the Chairman or Chief Executive Officer or Chief Financial Officer of the Company
and delivered to the Agent.  The Agent may rely upon such statement for any action taken or suffered in good faith by
it pursuant to the provisions of this Agreement.

 

7.4.2  Indemnity.  The
Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith.  The Company agrees
to indemnify the Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel
fees, for anything done or omitted by the Agent in the execution of this Agreement except as a result of the Agent’s gross
negligence, willful misconduct, or bad faith. 

 

7.4.3  Exclusions.  The
Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution
of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant
or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any determination regarding the
satisfaction of the Milestone by any Holder or make any adjustments required under the provisions of Section 4 hereof or responsible
for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any
such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or
reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of
Common Stock will, when issued, be valid and fully paid and nonassessable. 

 

    - 7 -

     

    

 

7.5  Acceptance
of Agency.  The Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon
the terms and conditions herein set forth. 

 

8. Miscellaneous
Provisions

 

8.1  Successors.  All
the covenants and provisions of this Agreement by or for the benefit of the Company or the Agent shall be binding upon, and inure
to the benefit of, their respective successors and assigns.

 

8.2  Notices.  Any
notice, statement or demand authorized by this Agreement to be given or made by the Agent or by the holder of any Warrant to or
on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or
private courier service within (i) five days after deposit of such notice, postage prepaid, or (ii) one business day following
delivery by fax, addressed (until another address is filed in writing by the Company with the Agent), as follows:

 

Wize
Pharma, Inc.

[●]

[●]

Attn:
[●]

Fax:
[●]

Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company
to or on the Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail
or private courier service within (i) five days after deposit of such notice, postage prepaid, or (ii) one business day following
delivery by fax, addressed (until another address is filed in writing by the Agent with the Company), as follows:

 

[●]

[●]

[●]

Attn:
[●]

Fax:
[●]

 

8.3  Applicable
Law.  The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all
respects by the laws of the State of New York, without giving effect to conflict of laws.  The Company hereby agrees
that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced
in the courts of the State of New York or the United States District Court for the SDNY, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive.  The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum.  Any such process or summons to be served upon the Company may be served
by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at
the address set forth in Section 8.2 hereof.  Such mailing shall be deemed personal service and shall be legal and binding
upon the Company in any action, proceeding or claim.

 

    - 8 -

     

    

 

8.4  Persons
Having Rights under this Agreement.  Nothing in this Agreement expressed and nothing that may be implied from any
of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than
the parties hereto and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement
or of any covenant, condition, stipulation, promise, or agreement hereof.  All covenants, conditions, stipulations,
promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their
successors and assigns and of the registered holders of the Warrants. 

 

8.5  Examination
of this Agreement.  A copy of this Agreement shall be available for inspection by the registered holder of any Warrant
at all reasonable times at the office of the Agent set forth in Section 8.2.  The Agent may require any such holder
to submit its Warrant for inspection by it.

 

8.6  Counterparts.  This
Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

8.7  Effect
of Headings.  The Section headings herein are for convenience only and are not part of this Agreement and shall
not affect the interpretation thereof. 

 

8.8  Amendments.  This
Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any ambiguity,
or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions
with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the
parties deem shall not adversely affect the interest of the registered holders.  All other modifications or amendments,
including any amendment to change the Milestone or Milestone Date, shall require the written consent of the registered holders
of a majority of the then outstanding Warrants.   

 

8.9  Severability.  This
Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof.  Furthermore, in lieu of any
such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement
a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

8.10  Certain
Definitions.  For the purposes hereof, the following terms shall have the following meanings:

 

“Closing
Date” shall mean [●], 2021.

 

    - 9 -

     

    

 

“Milestone”
means that the Holder has not, between the Closing Date and until the Milestone Date, (1) pledged, sold, transferred, contracted
to sell, sold or transferred any option or contract to purchase, purchased any option or contract to sell, granted any option,
right or warrant to purchase, or otherwise transferred or disposed of, directly or indirectly, all of the shares of Common Stock
issued to the Holder pursuant to the BIA and the Offer (such securities, collectively, “Covered Securities”),
or (2) entered into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of all of the Covered Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery
of Covered Securities, in cash or otherwise, in each case, other than by way of a Permitted Transfer (as defined below, subject
to applicable changes, including that the reference therein to Warrants shall be replaced by Covered Securities) of the Covered
Securities (each of the above, a “Covered Transfer”); provided that if the Holder effected a Covered Transfer
for part but not all of the Covered Securities, such Holder shall be deemed to have satisfied the Milestone, except that such
Holder’s entitlement to Warrant Shares shall be proportionally reduced and the number of Warrant Shares issuable to such
Holder shall be equal to the sum of (A) the portion (expressed in percentage) of the number of Covered Securities held by the
Holder on the Milestone Date (deducting any Covered Securities that were the subject of a Covered Transfer) compared to the total
number of Covered Securities issued to the Holder pursuant to the BIA and the Offer (the “Milestone Percentage”)
multiplied by (B) the maximum number of Warrant Shares issuable to such Holder pursuant to the BIA and the Offer if the
Holder shall have not effected any Covered Transfer until the Milestone Date. By way of illustration only of the foregoing,
if (i) a Holder was issued 100,000 shares of Common Stock on the Closing Date and warrants to purchase [●] Warrant Shares
and (ii) such Holder shall have sold, in the aggregate, 1,000 shares of Common Stock prior to the Milestone Date, then the Milestone
Percentage is 99% and such Holder will be entitled to receive [●] Warrant Shares.

 

“Milestone
Date” shall mean December 31, 2021.

 

“Permitted
Transfer” means a transfer of one or more Warrants (i) upon death of a Holder by will or intestacy, (ii) by instrument
to an inter vivos or testamentary trust in which the Warrants are to be passed to beneficiaries upon the death of the trustee,
(iii) pursuant to a court order (such as in connection with divorce, bankruptcy or liquidation), (iv) if the Holder is a partnership
or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or members,
as applicable; (v) a transfer made by operation of law (including a consolidation or merger) or in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other entity; provided that
as a condition to any such transfer, in each case, any such transferee shall take each such Warrant subject to the terms and conditions
of this Agreement and the Warrant and, if requested by the Company, shall sign and deliver to the Agent a written instrument agreeing
to be subject to and bound by the terms and conditions of this Agreement and the Warrant. 

 

“Securities
Act” means the United States Securities Act of 1933, as amended.

 

[SIGNATURE
PAGE TO FOLLOW]

  

    - 10 -

     

    

 

SCHEDULE
5 – FORM OF WARRANT AGREEMENT

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	[●],
                                         as Agent

	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

	Wize Pharma, Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

    - 11 -

     

    

 

EXHIBIT
A

 

FORM
OF WARRANT CERTIFICATE

 

[ENCLOSED]

 

 

 

 

 

 

 

 

 

 

    - 12 -

     

    

 

EXHIBIT
B

 

FORM
OF LIST OF HOLDERS

 

	NAME OF HOLDER	CONTACT INFO	NUMBER OF 

WARRANT SHARES1
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

1Note:
To reflect the maximum amount of Warrant Shares issuable to the Holder if the Milestone has been met.

 

    - 13 -

     

    

 

EXHIBIT
C

 

FORM
OF NOTICE OF TRANSFER

 

[ENCLOSED]

 

 

 

 

 

 

 

 

 

 

 

 

    - 14 -

     

    

 

EXHIBIT
D

 

FEES
AND EXPENSES OF AGENT

 

[Enclosed]

 

 

 

 

 

 

 

 

 

 

 

 -
15 -Exhibit 10.2

 

SCHEDULE 6 (FORM OF
CVR AGREEMENT)

 

CONTINGENT
VALUE RIGHTS AGREEMENT

 

THIS CONTINGENT
VALUE RIGHTS AGREEMENT, dated as of [●] [●], 2021 (this “Agreement”), is entered into
by and among Wize Pharma, Inc., a Delaware corporation (the “Company,” or “Wize”),
Cosmos Capital Limited (ACN 636 458 912), an Australian company (“Cosmos”), [●], Inc., a Delaware
corporation and a wholly owned subsidiary of the Company ("Wize US"), OcuWize Ltd., a company incorporated
under the laws of the state of Israel and a wholly owned subsidiary of Wize US (“OcuWize”), [_______], as the
Holders’ Representative (as defined herein), [●], as Rights Agent (the “Rights Agent”) and
as initial CVR Registrar (as defined herein).

 

RECITALS

 

WHEREAS, the Company
and Cosmos have entered into a Bid Implementation Agreement, dated as of December [●], 2020 (as it may be amended or supplemented
from time to time pursuant to the terms thereof, the “Acquisition Agreement”), pursuant to which the
Company conducted the Offer to acquire all the outstanding shares of Cosmos (the “Acquisition”);

 

WHEREAS, pursuant
to the Acquisition Agreement, the Company and Cosmos have agreed that the Company shall enter into this Agreement and issue one
non-transferrable CVR with respect to each CVR Eligible Security outstanding as of the Record Date; and

 

WHEREAS, each of
the Company and the Wize Subsidiaries has done all things necessary to make the CVRs, when issued in accordance with the Acquisition
Agreement and pursuant to this Agreement, the valid obligations of the Wize Subsidiaries, and to extent set forth herein, the Company;

 

NOW, THEREFORE, for
and in consideration of the premises and the consummation of the transactions referred to above, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, it is mutually covenanted and agreed, for the equal
and proportionate benefit of all Holders, as follows:

 

Article
I.  DEFINITIONS

 

Section 1.01 For
all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires:

 

(a) the
terms defined in this Article I have the meanings assigned to them in this Article I, and include the plural as well as the singular;

 

(b) all
accounting terms used herein and not expressly defined herein shall have the meanings assigned to such terms in accordance with
United States generally accepted accounting principles (U.S. GAAP), as in effect on the date hereof;

 

(c) the
words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement
as a whole and not to any particular Article, Section or other subdivision;

 

(d) unless
the context otherwise requires, words describing the singular number shall include the plural and vice versa, words denoting any
gender shall include all genders and words denoting natural Persons shall include corporations, partnerships and other Persons
and vice versa;

 

(e) all
references to “including” shall be deemed to mean including without limitation;

 

(f) unless
the context otherwise requires, if the doing of any act, matter or thing under this Agreement is dependent on the consent or approval
of a party or is within the discretion of a party and the consent or approval or discretion is qualified by the words “not
to be unreasonably withheld”, it shall mean not to be unreasonably withheld, conditioned or delayed; and

 

     

     

    

 

(g) all
references to an undertaking by Wize or Wize Subsidiaries to use “commercially reasonable efforts” shall be deemed
to mean that Wize or Wize Subsidiaries, as applicable, shall also cause its Affiliates to do so, and it being clarified that neither
the potential payment of the CVR Payment Amounts under this Agreement to CVR Holders, nor the lack of any economic interest to
Wize Subsidiaries or Wize in the LO2A Transactions (other than reimbursement of the Transaction Expenses) shall be taken into account
in determining the level of efforts to be exerted to take the applicable action.

 

Section 1.01 Capitalized
terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Acquisition Agreement. The
following terms shall have the meanings ascribed to them as follows:

 

“Affiliate”
means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls, is controlled by,
or is under common control with such specified Person, including, without limitation, any general partner, limited partner, member,
officer, director or manager of such Person and any venture capital or private equity fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. For purposes of
this definition, the terms “controls,” “controlled by,” or “under common control
with” means the possession, direct or indirect, of power to direct or cause the direction of management or policies (whether
through ownership of voting securities, by contract or otherwise). For the sake of clarity, the Wize Subsidiaries are deemed Affiliates
of the Company.

 

“BBG”
means Bonus BioGroup Ltd.

 

“BBG
Exchange Agreement” means that Exchange Agreement, dated as of January 9, 2020, between BBG and the Company, as amended
and supplemented from time to time, including by that Addendum to Exchange Agreement, dated as of December [ ], 2020, by and among
BBG, Wize, the Wize Subsidiaries and Wize IL.

 

“BBG
Expenses” means the sums payable to BBG under the BBG Exchange Agreement.

 

“Board”
means the board of directors of the Company. 

 

“Business
Day” means any day other than a Saturday, Sunday or a day on which banking institutions in New York, New York are
authorized or obligated by law or executive order to remain closed.

 

“Common
Stock” means the shares of common stock of the Company, par value $0.001 per share. 

 

“CVR
Derivative Security” means any security of the Company exercisable or convertible into Common Stock, the terms of
which provide for an adjustment, in the event of any distribution like the CVR, by way of participation in such distribution, as
is conclusively determined by the Board, and notified in writing to Rights Agent, at least three (3) Business Days prior to the
Record Date.

 

“CVR
Eligible Security” means, as of the Record Date, (i) each outstanding share of Common Stock and (ii) each outstanding
CVR Derivative Security. 

 

“CVR
Quarter” means the period beginning on the Effective Time and ending on the end of the first calendar quarter in
which the Effective Time occurs, and, thereafter, each full calendar quarter (January 1 through March 31; April 1 to June 30; July
1 to September 30; and October 1 through December 31 of each year) until the calendar quarter ending immediately after the Termination
Date (e.g., if the Termination Date falls on February 1, 2023, then the last CVR Quarter shall be the one ended on March 30, 2023).

 

    - 2 -

     

    

 

“CVRs”
means contingent value rights issued by Wize pursuant to the Acquisition Agreement and this Agreement, pursuant to which the Holders
are to receive contingent cash payments or other consideration pursuant to this Agreement, and each is referred to individually
as a “CVR.” 

 

“Effective
Time” means the date and time on which the Closing Date (as defined in the Acquisition Agreement) occurs. 

 

“Holder”
means a Person in whose name a CVR is registered in the CVR Register. 

 

“Holders’
Representative” means the representative of the Holders named in the preamble, until a successor Holders’ Representative
shall have become such pursuant to the applicable provisions of this Agreement, and thereafter “Holders’ Representative”
shall mean such successor Holders’ Representative.

 

“Intellectual
Property Rights” means any and all intellectual property rights, including without limitation (i) patents and patent
applications, including all reissues, renewals, reexaminations, extensions, supplementary protection certificates or equivalents
thereof, continuations, divisions, and continuations-in-part thereof; (ii) copyrights and all other rights corresponding thereto
throughout the world; (iii) rights associated with trademarks, service marks, trade names, trade dress, domain names, logos
and similar rights, and the goodwill associated therewith, whether registered or unregistered; (iv) trade secrets and know-how;
and (viii) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world, including the right
to seek remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions. 

 

“Last
CVR Entitlement Date” means the last date on which an entitlement (including entitlement for any escrow, earnout
or other contingent payment) arises to receive consideration under any LO2A Transaction Agreement.

 

“LO2A
Advisor Agreements” means engagement letter agreements of either the Company, its Affiliates or the Holders’
Representative with investment bankers, legal counsel and other professional advisors that Holders’ Representative believes,
in good faith, will help facilitate exploring, pursuing and/or consummating an LO2A Transaction.

 

“LO2A
Business” means the business of monetizing any LO2A Product or use or development or other exploitation of the LO2A
Technology or of any of the Company’s rights therein, directly or indirectly.

 

“LO2A
Product” means (i) any product, that comprise, contain or incorporate, in whole or in part, LO2A Technology, (ii)
the development, production and/or sale of which is based on, or involves, in whole or in part, the use of LO2A Technology, (iii)
products which are produced or manufactured, in whole or in part, using a process, method or system covered by, or falling within,
the LO2A Technology, or (iv) any other use, commercialization and/or exploitation of the LO2A Technology in any manner whatsoever
and for any purpose or indication whatsoever with respect to all of the foregoing.

 

“LO2A
Technology” means any invention, know-how or other Intellectual Property Rights owned by or licensed to Wize and/or
any of its Affiliates prior to, on and/or after the date hereof in connection with, based on and/or as a result of the use of the
formula developed by Resdevco for the treatment of dry eye syndrome, and other ophthalmological illnesses, including Conjunctivochalasis
and Sjögren’s syndrome, but specifically excludes: (a) any invention, know-how or other Intellectual Property Rights
owned by or licensed to Cosmos and/or any of its Affiliates prior to the date hereof, (b) any invention, know-how or other Intellectual
Property Rights owned by or licensed to Cosmos and/or any of its Affiliates on or following the date hereof in connection with
digital asset infrastructure or in connection with any other business that is not related to the LO2A Business, and (c) rights
associated with trademarks, service marks, trade names, trade dress, domain names, logos and similar rights, and the goodwill associated
therewith, whether registered or unregistered, of the name “Wize Pharma” or similar variations that do not include
the LO2A Business; provided however that, in the event of an LO2A Transaction that involves the sale of any Wize Subsidiary, the
LO2A Transaction Agreement may provide that the acquiror may keep using the corporate name of such subsidiaries for up to 90 days
after consummation of such LO2A Transaction.

 

    - 3 -

     

    

 

“Majority
of CVR Holders” means, as of any date, written consent of the Holders holding a majority of the outstanding CVRs
as of such date (or, if at the Holders’ Representative decision, a meeting of the Holders of CVRs is convened in order to
obtain the approval of the Holders hereunder, the Holders of a majority of the outstanding CVRs as of such date that are present
and voting, by person or proxy, at such meeting); for this purpose, CVRs beneficially owned by the Company or by any Affiliate
of the Company shall be considered as though not outstanding.  

 

“Officer’s
Certificate” means a certificate signed by the chief executive officer, president or chief financial officer of the
applicable party in his or her capacity as such, and delivered to the Rights Agent.

 

“Permitted
Liabilities” mean (A) costs, obligations or liabilities that would constitute Transaction Expenses, (B) obligations
or liabilities (as opposed to costs) that are immaterial in nature, taking into account that the primary business of the Company
following the Closing is not related to the LO2A Business, and (C) costs, obligations or liabilities that are executory in nature
and are primarily related to the corporate existence of the Company or the Wize Subsidiaries or the due authorization (and required
third party consents) of the action being authorized and/or representations and warranties regarding, if applicable, financial
statements of the Company or the Wize Subsidiaries (subject to customary materiality qualifications) if such financial statements
cover periods beyond the Effective Time. 

 

“Permitted
Transfer” means a transfer of one or more CVRs (i) upon death of a Holder by will or intestacy, (ii) by instrument
to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee, (iii)
pursuant to a court order; (such as in connection with divorce, bankruptcy or liquidation), (iv) if the Holder is a partnership
or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or members,
as applicable; (v) a transfer made by operation of law (including a consolidation or merger) or in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other entity; provided that
as a condition to any such transfer, in each case, any such transferee shall take each such CVR subject to the terms and conditions
of this Agreement and, if requested by the Company, shall sign and deliver to the Rights Agent a written instrument agreeing to
be subject to and bound by the terms and conditions of this Agreement. 

 

“Person”
means any natural person, corporation, partnership, limited liability company, trust, estate, other firm or entity or governmental
body. 

 

“Resdevco”
means Resdevco Ltd.

 

“Resdevco
Agreement” means that Exclusive Distribution and Licensing Agreement between Wize IL (including OcuWize) and Resdevco,
dated as of May 1, 2015, as amended and supplemented from time to time.

 

“Resdevco
Expenses” means the sums payable to Resdevco under the Resdevco Agreement and the sums of any reasonable out of pocket
expenses associated with or arising out of performing any and all obligations arising out of the Resdevco Agreement.

 

“Rights
Agent” means the Rights Agent named in the Preamble to this Agreement, until a successor Rights Agent shall have
become such pursuant to the applicable provisions of this Agreement, and thereafter “Rights Agent” shall mean such
successor Rights Agent. 

 

    - 4 -

     

    

 

“Transaction Expenses” means the following to the extent incurred by Wize or any of the Wize Subsidiaries
after the Effective Time and prior to the applicable measurement date (i.e., prior to the scheduled distribution of the CVR Payment
Amount); provided that any following item is documented and without double counting: (i) the Post-Closing LO2A Investment actually
incurred and paid; (ii) all taxes incurred and paid (and that are not otherwise credited or offset) by the Company or its Affiliates
during the relevant period and that are a direct result from the consummation of the LO2A Transaction (such as transfer taxes,
if any); (iii) all out of pocket transaction expenses (including any broker fees, accountant or attorney’s fees) incurred
by the Company or any of its Affiliates as a result of an LO2A Transaction; provided such transaction expenses (or the terms of
engagement therefor) were previously approved in writing by the Holders’ Representative (not to be unreasonably withheld);
(iv) any costs or expenses relating to the Company’s obligations under Sections 3.03(g), 3.03(h),
5.04 and/or 5.05; (v) the Resdevco Expenses; provided that no amendment to the Resdevco Agreement was made following
the Effective Time without the prior written approval of the Holders’ Representative; (vi) the BBG Expenses; provided that
no amendment to the BBG Exchange Agreement was made following the Effective Time without the prior written approval of the Holders’
Representative; (vii) all reasonable attorney fees expended or incurred in connection with reviewing any actions to be taken by
the Company at the request by the Holders’ Representative; (viii) all costs and expenses for the W&I Insurance or the
Indemnity Escrow, if applicable; and (ix) such other liabilities, costs or expenses that the Holders’ Representative or the
Majority of CVR Holders agree to be treated as Transaction Expenses. For the sake of clarity, unless otherwise expressly agreed
otherwise, any costs and expenses incurred by the Company or its Affiliates in compliance with this Agreement or arising from any
dispute arising therefrom shall not be considered Transaction Expenses.

 

“Wize
IL” means Wize Pharma Ltd., an Israeli limited company and a wholly owned subsidiary of Wize.

 

“Wize
Subsidiaries” mean Wize US, OcuWize, and, without derogating from the Company’s obligations hereunder (including
Section 4.03), any other subsidiary of the Company or Wize US to the extent it holds, directly or indirectly, any equity interest
in OcuWize Ltd.

 

Article
II. CONTINGENT VALUE RIGHTS; LO2A TRANSACTION

 

Section
2.01  Issuance of CVRs; Appointment of Rights Agent.

 

(a) At
the Effective Time, Wize shall issue to Holders one CVR for each CVR Eligible Security held of record by such Holder as of 4:01 p.m.
Eastern Time on the day immediately before the Effective Time (the “Record Date”).

 

(b) Wize
hereby appoints the Rights Agent in accordance with the express terms and conditions of this Agreement, and the Rights Agent hereby
accepts such appointment.

 

(c) Distribution
of any CVR Payment Amount to Holders shall be made in accordance with such Holder’s proportion of the aggregate outstanding
CVRs as reflected in the CVR Register from time to time.

 

Section 2.02 Nontransferable.

 

The CVRs shall not
be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other
than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance or disposition of any CVR or any
right or interest therein, in whole or in part, in violation of this ‎Section
2.02 shall be void ab initio and of no effect. The CVRs will not be listed on any quotation system or traded on any securities
exchange.

 

Section 2.03 No
Certificate; Registration; Registration of Transfer; Change of Address.

 

(a) The
CVRs shall be issued in book-entry form only and shall not be evidenced by a certificate or other instrument.

 

    - 5 -

     

    

 

(b) The
Company shall furnish or cause to be furnished to the Rights Agent in such form as the Company receives from its transfer agent
(or other agent performing similar services for the Company), and which is reasonably satisfactory to the Rights Agent, the names,
addresses and numbers of CVR Eligible Security held as of the Record Date of those Persons entitled to receive CVRs pursuant to
this Agreement and the Acquisition Agreement.

 

(c) The
Rights Agent shall keep a register (the “CVR Register”) for the registration of CVRs. The Rights Agent
is hereby initially appointed as the CVR registrar and transfer agent (“CVR Registrar”) for the purpose
of registering CVRs and transfers of CVRs as herein provided. Upon any change to the identity of the Rights Agent in accordance
with the terms of this Agreement, the successor Rights Agent shall automatically also become the successor CVR Registrar.

 

(d) Subject
to the restrictions on transferability set forth herein, every request made to transfer a CVR must be in writing and accompanied
by a written instrument or instruments of transfer and accompanied by a signature guarantee and such other documentation as the
Rights Agent or CVR Registrar may reasonably request, duly executed by the registered Holder or Holders thereof or by the duly
appointed legal representative, personal representative or survivor of such Holder or Holders or by a duly authorized attorney-in-fact,
setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written request and materials,
the CVR Registrar shall, subject to its reasonable determination that the transfer instrument is in proper form, register the transfer
of the CVRs in the CVR Register. All duly transferred CVRs registered in the CVR Register shall remain the valid obligations of
the Wize Subsidiaries, and to extent set forth herein, the Company, evidencing the same right and shall entitle the transferee
to the same benefits and rights under this Agreement, as those previously held by the transferor. No transfer of a CVR shall be
valid until registered in the CVR Register, and any transfer not duly registered in the CVR Register will be void ab initio. Any
transfer or assignment of the CVRs shall be without charge (other than the cost of any transfer tax which shall be the sole responsibility
of the transferor) to the Holder; it being clarified that the Rights Agent may charge the Company a fee therefor in accordance
with this Agreement.

 

(e) A
Holder may make a written request to the CVR Registrar to change such Holder’s address of record in the CVR Register. The
written request must be duly executed by the Holder. Upon receipt of such written notice, the CVR Registrar shall promptly record
the change of address in the CVR Register.

 

Section 2.04 LO2A
Transaction; CVR Payment Amount.

 

(a) During
the period commencing on the Effective Time and ending on the earlier of (i) the LO2A Termination Date (as defined below) and (ii)
the second-year anniversary of the Effective Time (the “Transaction Term”), each of the Company and the
Wize Subsidiaries hereby authorizes (and shall cause the Wize Subsidiaries, if any are formed and for so long as they have not
countersigned this Agreement, to authorize) the Holders’ Representative, and the Holders’ Representative hereby agrees
to use its good faith efforts, to pursue, explore, discuss and negotiate the terms of a transaction, or a series of transactions
(whether related or not), for the monetization of the Wize Subsidiaries’ rights in the LO2A Technology, including through
(i) a sale of any of the Wize Subsidiaries to a third party and/or (ii) partnering, licensing, sublicensing, distribution, reselling
or sale of all or any part of the LO2A Technology or LO2A Products to a third party (each, an “LO2A Transaction”).
The Holders’ Representative shall be solely authorized for all matters and actions in respect of (i) any LO2A Transaction,
including identifying appropriate third parties, negotiating with such third parties and, subject to Section 2.04(b),
executing and consummating any LO2A Transaction, (ii) in connection therewith, any decision to amend or modify the Resdevco Agreement
and/or the BBG Exchange Agreement, so long as such amendment or modification does not impose any additional cost, obligation or
liability on the Company (other than Permitted Liabilities) and, subject to Section 2.04(b), executing and consummating
such amendment(s) or modification(s) (the “Resdevco/BBG Amendment”), and (iii) terminating the Resdevco Agreement,
if no LO2A Transaction Agreement is entered prior to such termination decision (the date such termination becomes effective, the
“LO2A Termination Date”). Without derogating from the generality of the foregoing, Wize shall (i) empower the
Holders’ Representative to designate any and all members of the Board of Directors of Wize US (and, thereby, OcuWize), and
(ii) empower the Holders’ Representative to manage, or designate any other person who will manage, Wize ownership rights
in Wize US in view of the interests of the Holders and in accordance with this Agreement and the BBG Exchange Agreement; provided
that the foregoing should not be construed as imposing any additional obligations on Wize beyond those expressly specified
in the this Agreement. The Wize Subsidiaries, and to extent necessary, the Company, shall provide reasonable assistance to the
Holders’ Representative in respect of any LO2A Transaction, Resdevco/BBG Amendment, and/or such termination decision, including
providing the Holders’ Representative with reasonable access to the Company’s and its Affiliates’ books, records,
documents, personnel and other reasonably requested information; provided that if such information is not readily in the possession
of the Company or its Affiliates and would require the preparation of any information, the costs and reasonable expenses therefor
would be considered Transaction Expenses if the Company so informs the Holders’ Representative in writing prior thereto.

 

    - 6 -

     

    

 

(b) Without
derogating from Section 4.04 below, each of the Wize Subsidiaries, and to extent necessary, the Company, undertakes to provide
reasonable support (and shall cause the Wize Subsidiaries, including those not countersigning this Agreement, to support), the
cost of which support, if (x) requires the support of any third parties or the devotion of substantial internal resources and (y)
the Company so informs the Holders’ Representative in writing prior thereto, shall be considered Transaction Expenses, (i)
any proposed LO2A Transaction presented by the Holders’ Representative and to approve entry into such transaction (including
causing the execution of the LO2A Transaction Agreement), (ii) any LO2A Advisor Agreements presented by the Holders’ Representative
(including causing the execution thereof), and (iii) any proposed Resdevco/BBG Amendment presented by the Holders’ Representative
and to approve entry into such transaction (including causing the execution of any Resdevco/BBG Amendment), unless the Company
shall have reasonably determined that such LO2A Transaction Agreement, LO2A Advisor Agreements or Resdevco/BBG Amendment, as the
case may be, would subject the Company to (A) any additional cost or expense that would not constitute a Transaction Expense, or
(B) any other liability for which Company would not be indemnified, in each case, other than Permitted Liabilities. Notwithstanding
anything to the contrary herein, it is hereby agreed that unless Company consents in writing otherwise, which it may withhold in
its good faith discretion, the terms for any LO2A Transaction must provide that, other than Permitted Liabilities, the Company
is not liable for the breach of any representation, warranty or covenant made in connection with the LO2A Transaction, except to
the extent that the liability for such breach is paid solely (i) out of an escrow established with LO2A Consideration to cover
breach of representations, warranties and covenants of Company (the “Indemnity Escrow”), (ii) by representation
and warranty or warranty and indemnity insurance (or a similar product) (“W&I Insurance”) purchased in connection
with the LO2A Transaction with LO2A Consideration, and/or (iii) out of any earn-out, contingent payment or similar payment of the
LO2A Consideration ) after Company has reimbursed itself for all Transaction Expenses.

 

(c)   If
(i) the Wize Subsidiaries and, to extent applicable, the Company shall have complied with its obligations hereunder and (ii) the
Wize Subsidiaries and, to extent applicable, the Company shall not have entered into a definitive binding agreement in respect
of an LO2A Transaction (an “LO2A Transaction Agreement”) during the Transaction Term, then, any time
thereafter the Board may, in its good faith discretion, elect to terminate this Agreement or, if so requested in writing by the
Holders’ Representative, the parties shall terminate this Agreement (the date of such election, the “Program
Termination Date”); in which case, the Company shall provide written notice of such termination to the Rights Agent
and the Holders’ Representative. This Agreement and all CVRs shall terminate automatically, and without any action on the
part of the Company, the Wize Subsidiaries, the Rights Agent, any Holder, the Holders’ Representative or any other Person,
on the Program Termination Date.

 

(d) The
Wize Subsidiaries, and to extent applicable, the Company shall promptly deliver (or cause its Affiliates to deliver) to the Rights
Agent for the ratable benefit of the Holders, in accordance with the payment procedures set forth in Section 2.06,
any consideration (whether cash, stock, assets or otherwise) that the Wize Subsidiaries, or to extent applicable, the Company (or
any of its Affiliates or shareholders) received in connection with the LO2A Transaction Agreement(s) (“LO2A Consideration”)
net of all Transaction Expenses not previously reimbursed to the Company or any of its Affiliates (such net consideration distributed,
a “CVR Payment Amount”). If any LO2A Consideration (i) received by the Wize Subsidiaries, or to extent
applicable, the Company (or any of its Affiliates or shareholders) is a combination of cash and non-cash consideration, then the
Wize Subsidiaries, or to extent applicable, the Company may, at its election, set off all Transaction Expenses first against the
cash portion of such LO2A Consideration before distributing any CVR Payment Amount pursuant to this Section 2.04(d),
or (ii) consists of funds or other consideration that are placed in escrow or are contingent, then the LO2A Consideration (and
consequently, the CVR Payment Amount) shall initially be calculated without such escrowed funds and/or contingent consideration,
and once released or otherwise received by the Wize Subsidiaries or, to extent applicable, the Company (or any of its Affiliates
or shareholders), it shall be calculated as part of the LO2A Consideration (and consequently, the CVR Payment Amount).

 

    - 7 -

     

    

 

Section 2.05 Payment
Procedures.

 

(a) Within
ten (10) Business Days following receipt of any LO2A Consideration by the Wize Subsidiaries, or to the extent applicable, by Wize,
Wize shall deliver to the Rights Agent (x) an Officer’s Certificate certifying the CVR Payment Amount, if any, received by
the Wize Subsidiaries, or to the extent applicable, Wize (or its Affiliates), with a copy to the Holders’ Representative
(the “CVR Certificate”) and (y) the CVR Payment Amount. If the CVR Payment Amount is to be paid in cash,
then such amount will be transferred by wire transfer of immediately available funds to an account designated in writing by the
Rights Agent, the applicable CVR Payment Amount, if any. To the extent that any CVR Payment Amount is paid to the Rights Agent,
such amounts shall be treated for all purposes of this Agreement as having been paid to the Holders and any delay, failure or mistake
in payment by Rights Agent shall not be the liability or obligation of Wize or the Wize Subsidiaries, as applicable (it being clarified
such delay, failure or mistake in payment by Rights Agent being treated, and subject to the liability limitations, set forth in
Article III). If the Wize Subsidiaries, or to the extent applicable, the Company fails to timely deliver the CVR Payment Amount
(as may be adjusted upwards following resolution of a disagreement underlying a Notice of Objection) due hereunder to the Rights
Agent, other than due to reasons which are a ‘force majeur’ or act of God, then, without derogating from the other
rights and remedies available herein, such CVR Payment Amount shall bear a default interest of 6% per annum (from the date it was
due until the transfer date) and such default interest shall be added to, and become part of, the CVR Payment Amount.

 

(b)   On
or prior to the 10th Business Day immediately following delivery of the CVR Certificate and the applicable CVR Payment
Amount to the Rights Agent in accordance with Section 2.05, the Rights Agent shall (i) send each Holder a copy of such CVR Certificate
to such Holder’s registered address and (ii) distribute the CVR Payment Amount, if any, to the Holders pro rata in accordance
with their respective CVRs as reflected on the CVR Register, by checks (if such payment is to be made in cash) mailed to the respective
addresses of such Holders as reflected in the CVR Register (the earlier of such 10th Business Day and the date on which
the Rights Agent distributes the CVR Payment in accordance with this subsection(b), in each case if a CVR Payment Amount shall
have been required to be delivered to the Rights Agent in accordance with Section 2.05, the “CVR Payment Date”).

  

(c)  The
Wize Subsidiaries, or to the extent applicable, Wize shall be entitled to deduct and withhold, or cause to be deducted or withheld,
from each CVR Payment Amount otherwise payable pursuant to this Agreement, such amounts as Wize or the applicable subsidiary of
Wize is required to deduct and withhold with respect to the making of such payment under the U.S. Internal Revenue Code of 1986,
as amended, or any provision of state, local or foreign tax law. To the extent that amounts are so withheld or paid over to or
deposited with the relevant governmental entity, such withheld amounts shall be treated for all purposes of this Agreement as having
been paid to the Holders in respect of which such deduction and withholding was made. The Wize Subsidiaries, or to the extent applicable,
the Company and the Holders’ Representative may agree to defer any payment of the CVR Payment Amount as needed to secure
a tax ruling or other procedure that would allow Wize to refrain from deducting or reduce the amount to be deducted, at source
from the CVR Payment Amount.

 

(d)  Any
portion of a CVR Payment Amount that remains undistributed by the Rights Agent to the Holders (including by means of uncashed checks
or invalid addresses on the CVR Register) twelve (12) months after the relevant CVR Payment Date shall be delivered by the Rights
Agent to Wize, and any Holder shall thereafter look only to Wize for payments of such CVR Payment Amount, without interest, but
such Holder shall have no greater rights against Wize than those accorded to general unsecured creditors of Wize under applicable
law. Neither Wize nor the Rights Agent shall be liable to any Holder in respect of any cash delivered to a public official in compliance
with any applicable state, federal or other abandoned property, escheat or similar law. If any checks delivered pursuant to the
provisions hereof shall not have been cashed prior to the date on which the cash in respect of such checks would otherwise escheat
to or become the property of any governmental authority, any cash in respect of such checks shall, to the extent permitted by law,
immediately prior to such time become the property of Wize. Thereafter, Wize shall be responsible for compliance with unclaimed
property obligations.

 

    - 8 -

     

    

 

Section 2.06. 
Reporting.

 

(a) If
the Company shall not have delivered a CVR Certificate pursuant to Section 2.05 in any CVR Quarter, then, no later than 15 days
following the end of such CVR Quarter, the Company shall deliver to the Rights Agent, with a copy to the Holders’ Representative,
an Officer Certificate indicating that no CVR Payment Amount was due in respect of such CVR Quarter (a “Non-Achievement
Certificate”). The Rights Agent shall promptly (and in no event later than ten (10) Business Days after receipt thereof)
send each Holder a copy of the Non-Achievement Certificate at the address reflected in the CVR Register as of the date the Rights
Agent received such Non-Achievement Certificate.

 

(b) Upon
written demand by the Majority of CVR Holders (which demand must be in writing, with a copy to the Holders’ Representative
and the Rights Agent) or the Holders’ Representative within thirty (30) calendar days after either (i) distribution
by the Rights Agent of a Non-Achievement Certificate or (ii) distribution by the Rights Agent of a CVR Certificate (the “Objection
Period”), the Holders’ Representative shall deliver a written notice to Wize (i) specifying that the Holders’
Representative or Majority of CVR Holders objects to the determination and/or calculation of Wize set forth in the Non-Achievement
Certificate or CVR Certificate, as applicable, and (ii) setting forth in reasonable detail the basis upon which the Holders’
Representative or Majority of CVR Holders have determined that a CVR Payment Amount is in fact payable for the applicable CVR Quarter
or that the amount of the CVR Payment Amount should be higher, as applicable (a “Notice of Objection”).
Any dispute arising from a Notice of Objection shall be resolved in accordance with the procedure set forth in Section 8.06, which
decision shall be binding on the parties hereto and every Holder; it being clarified that the delivery of a Notice of Objection
shall not relieve the Wize Subsidiaries or, to extent the applicable, the Company from payment of the CVR Payment Amount set forth
in its initial CVR Certificate.

 

(c) If
a Notice of Objection has not been delivered to Wize within the Objection Period, then the Non-Achievement Certificate or CVR Certificate,
as applicable, shall not be subject to any challenge by the Holders’ Representative or any Holder, and the Rights Agent shall
have no further obligations with respect to such Non-Achievement Certificate or CVR Certificate, as applicable.

 

(d)  Wize
shall promptly furnish (and in no event later than ten (10) Business Days after receipt of a written request) to the Rights
Agent and the Holders’ Representative all information and documentation in connection with this Agreement and the CVRs that
the Rights Agent or the Holders’ Representative may reasonably request in connection with the determination of whether a
CVR Payment Amount is due and the sum thereof, which information shall be used solely in connection with this Agreement and the
transactions contemplated hereby and shall be subject to the obligations set forth in Section 8.14.

 

Section 2.07. No
Voting, Dividends or Interest; No Equity or Ownership Interest in Wize.

 

(a) The
CVRs shall not have any voting or dividend rights, and, except as expressly set forth otherwise herein, interest shall not accrue
on any amounts payable, if any, on the CVRs to any Holder.

 

(b) The
CVRs shall not represent any equity or ownership interest in the Company. The rights of the Holders are limited to those expressly
set forth in this Agreement, and Holders’ sole right to receive property hereunder is the right to receive CVR Payment Amounts,
if any, through the Rights Agent in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not
constitute a security of Wize.

 

    - 9 -

     

    

 

(c) By
accepting a CVR, each Holder is deemed to acknowledge and agree to the appointment and authority of the Holders’ Representative
to act as the exclusive representative, agent and attorney-in-fact of such Holder and all Holders as set forth in this Agreement.
By accepting a CVR, each Holder agrees that such Holder will not challenge or contest any action, inaction, determination or decision
of the Holders’ Representative or the authority or power of the Holders’ Representative and will not threaten, bring,
commence, institute, maintain, prosecute or voluntarily aid any action, which challenges the validity of or seeks to enjoin the
operation of any provision of this Agreement, including, without limitation, the provisions related to the authority of the Holders’
Representative to act on behalf of such Holder and all Holders as set forth in this Agreement. If a Holder brings, commences, institutes,
maintains, prosecutes or voluntarily aids any such action, then such Holder shall lose all rights under this Agreement and under
such Holder’s CVRs, including, without limitation, the right to receive any payments under this Agreement or in connection
with any CVR.

 

(d) The
Wize Subsidiaries and Wize may rely upon any written decision, act, consent or instruction of the Holders’ Representative
as being the decision, act, consent or instruction of every Holder. The Wize Subsidiaries and Wize are hereby relieved from any
liability to any Holder for any acts done by them in accordance with such written decision, act, consent or instruction of Holders’
Representative.

 

Section 2.08. Amendments
to LO2A Transaction Agreement.

 

Notwithstanding anything
contained herein to the contrary, neither Wize nor the Wize Subsidiaries or Affiliates thereof shall amend any LO2A Transaction
Agreement, Resdevco Agreement and/or BBG Exchange Agreement, or waive any right thereunder, unless the Holders’ Representative
or the Majority of CVR Holders consents in writing to each such amendment or waiver.

 

Section 2.09. Ability
to Abandon CVRs.

 

A Holder may at any
time, at such Holder’s option, abandon all of such Holder’s remaining rights in a CVR by transferring such CVR to Wize
without consideration therefor.

 

ARTICLE
III.

THE RIGHTS AGENT

 

Section 3.01. Certain
Duties and Responsibilities.

 

(a) The
Rights Agent shall be authorized and protected and shall not have any liability for, or in respect of any actions taken, suffered
or omitted to be taken by it in connection with this Agreement and the exercise and performance of its duties hereunder, except
to the extent such liability is a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (each as
determined by a final, non-appealable judgment of a court of competent jurisdiction) and subject to the limitations set forth herein,
including section 3.01(b) below. No provision of this Agreement shall require the Rights Agent to expend or risk its own funds
or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights
or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably
assured to it. Notwithstanding anything in this Agreement to the contrary, except for a failure to distribute the CVR Payment Amount,
if any, to the Holders pro rata in accordance with their respective CVRs as reflected on the CVR Register, any liability of the
Rights Agent under this Agreement will be limited to the amount of annual fees (excluding any reimbursed costs and expenses) paid
by the Company to the Rights Agent during the twelve (12) months immediately preceding the event for which recovery from the Rights
Agent is being sought.

 

(b) Anything
to the contrary notwithstanding, in no event will the Rights Agent be (i) liable for special, punitive, or consequential loss or
damages (including, without limitation, lost profits) or (ii) required to take actions that are beyond its express duties hereunder.

 

(c) The
Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any CVR Holder with
respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility
to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company.

 

    - 10 -

     

    

 

Section 3.02. Merger
or Consolidation or Change of Name of Rights Agent.

 

(a) Any
corporation or limited liability company or other entity into which the Rights Agent or any successor Rights Agent may be merged
or with which it may be consolidated, or any corporation or limited liability company or other entity resulting from any merger
or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any corporation or limited liability
company succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent,
shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act
on the part of any of the parties hereto, provided that such corporation or limited liability company or other
entity would be eligible for appointment as a successor Rights Agent under the provisions of Section 3.04. The purchase of all
or substantially all of the Rights Agent’s assets employed in the performance of transfer agent activities shall be deemed
a merger or consolidation for purposes of this Section 3.02. In case at the time such successor Rights Agent shall succeed to the
agency created by this Agreement, any of the CVR Certificates shall still have the full force provided in the CVR Certificates
and in this Agreement.

 

(b) In
case at any time the name of the Rights Agent shall be changed and at such time any of the CVR Certificates shall have not been
delivered, such CVR Certificates shall still have the full force provided in the CVR Certificates and in this Agreement.

 

Section 3.03. Certain
Rights of Rights Agent.

 

(a) the
Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied
duties, covenants or obligations shall be read into this Agreement against the Rights Agent;

 

(b) the
Rights Agent may rely and shall be authorized and protected in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order, power of attorney, endorsement, affidavit,
letter or other paper or document believed by it to be genuine and to have been signed or presented by an officer of the proper
party or parties or upon any written instructions or statements from the Company, the Wize Subsidiaries or the Holders’ Representative
(the authorized representatives thereof are all listed in Schedule 3) with respect to any matter relating to its role as Rights
Agent hereunder. The Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice
thereof hereunder but as to which no notice was provided, and the Rights Agent shall be fully protected and shall incur no liability
for failing to take any action in connection therewith unless and until it has received such notice;

 

(c) whenever
the Rights Agent shall deem it necessary or desirable that any fact or matter be proved or established before taking, suffering
or omitting any action hereunder, the Rights Agent may request and rely upon an Officer’s Certificate from the Company with
respect to such fact or matter; and such certificate shall be full and complete authorization and protection to the Rights Agent
and the Rights Agent shall incur no liability for or in respect of any action taken, suffered or omitted to be taken by it under
the provisions of this Agreement in reliance upon such certificate. The Rights Agent shall be fully authorized and protected in
relying upon the most recent instructions received from the Company. In the event the Rights Agent believes any ambiguity or uncertainty
exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights
Agent hereunder, the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and
shall not be liable in any way to the Company or any other Person for refraining from taking such action, unless the Rights Agent
receives written instructions from the Company, with a concurrent copy to the Holders’ Representative, that eliminates such
ambiguity or uncertainty to the satisfaction of the Rights Agent;

 

(d) the
Rights Agent may engage and consult with counsel (who may be legal counsel of the Company or an employee or legal counsel of the
Rights Agent) and the Rights Agent may rely on the advice of such counsel or any opinion of counsel in respect of any action taken,
suffered or omitted to be taken by it hereunder in reliance thereon in the absence of willful misconduct, bad faith or gross negligence
on the part of the Rights Agent (as determined by a final, non-appealable judgment of a court of competent jurisdiction);

 

    - 11 -

     

    

 

(e) the
permissive rights of the Rights Agent to perform actions enumerated in this Agreement shall not be construed as a duty;

 

(f) the
Rights Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise;

 

(g) Wize
agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine,
penalty, claim, demand, suit, settlement, cost or expense (including, without limitation, the reasonable fees and out-of-pocket
expenses of legal counsel) incurred, absent willful misconduct, bad faith or gross negligence on the part of the Rights Agent (the
occurrence of each as determined by a final, non-appealable judgment of a court of competent jurisdiction), for any action taken,
suffered or omitted to be taken by the Rights Agent in connection with the acceptance and administration of this Agreement, or
the exercise or performance of its duties hereunder, including, without limitation, the reasonable out of pocket costs and expenses
of defending against any claim of liability hereunder and in enforcing this right of indemnification;

 

(h) Wize
agrees to pay to, and shall be liable for, the Rights Agent fees and expenses in connection with this Agreement (“Rights
Agent Fees and Expenses”), as set forth on Schedule 1 hereto, and further including reimbursement of the Rights
Agent for all taxes and charges, reasonable out-of-pocket expenses and other charges of any kind and nature, including reasonable
fees and expenses of the Rights Agent’s counsel and agent, (other than taxes measured by the Rights Agent’s net income),
paid or incurred by the Rights Agent in connection with the preparation, negotiation, delivery, amendment, administration and execution
by the Rights Agent of this Agreement and its duties hereunder;

 

(i) the
Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or be
required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company or Holders’
Representative only, as applicable;

 

(j) the
Rights Agent shall not have any liability for or be under any responsibility in respect of the validity of this Agreement or the
execution and delivery hereof; nor shall it be responsible for any breach by the Company of any covenant or failure by the Company
to satisfy conditions contained in this Agreement;

 

(k) the
Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered
all such further and other acts, instruments and assurances as may reasonably be required or requested by the Rights Agent for
the carrying out or performing by the Rights Agent of its duties under this Agreement;

 

(l) the
Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the LO2A Transaction
Agreement or any other agreement between or among any of the Company, the Holders’ Representative or any other parties hereto,
even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction, request or other
communication, paper or document other than as expressly set forth in this Agreement;

 

(m) the
Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself
or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, omission, default,
neglect or misconduct of any such attorneys or agents or for any loss to the Company, to the Holders, the Holders’ Representative
or any other Person resulting from any such act, omission, default, neglect or misconduct, absent gross negligence or bad faith
in the selection and continued employment thereof (which gross negligence or bad faith must be determined by a final, non-appealable
judgment of a court of competent jurisdiction) and, in the event of arbitration or litigation in connection with the matters contemplated
herein, the Rights Agent may, but shall not be obligated to, engage and consult with tax experts, valuation firms and other experts
and third parties that it, in its sole and absolute discretion, deems appropriate or necessary to enable it to discharge its duties
hereunder;

 

    - 12 -

     

    

 

(n) nothing
herein shall preclude the Rights Agent or any of its Affiliates from acting in any other capacity for the Company or for any other
Person; and

 

(o) the
provisions of ‎0 and this  ‎0 shall
survive the expiration of the CVRs, the termination of this Agreement, the payment of any distributions made pursuant to this Agreement,
and the resignation, replacement or removal of the Rights Agent hereunder.

 

Section 3.04. Resignation
and Removal; Appointment of Successor.

 

(a) The
Rights Agent and any successor Rights Agent may resign and be discharged from its duties under this Agreement at any time by giving
written notice thereof to the Company and the Holders’ Representative, specifying a date when such resignation shall take
effect, which notice shall be sent at least thirty (30) days before the date so specified. The Company may remove the Rights Agent
or any successor Rights Agent at any time by giving written notice thereof to the Rights Agent and the Holders’ Representative
specifying a date when such removal shall take effect, which notice shall be sent at least thirty (30) days before the date so
specified. In the event any transfer agency relationship in effect between the Company and the Rights Agent terminates, the Rights
Agent will be deemed to have resigned automatically and be discharged from its duties under this Agreement as of the effective
date of such termination, and the Company shall be responsible for sending any required notice hereunder.

 

(b) If
the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor
to the Rights Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after giving notice
of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights
Agent, then the Holders’ Representative may apply to any court of competent jurisdiction for the appointment of a new Rights
Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be either (a) a Person organized
and doing business under the laws of the United States or of any state of the United States that is authorized under such laws
to exercise corporate trust or stock transfer powers and is subject to supervision or examination by federal or state authority
and that has, along with its Affiliates, at the time of its appointment as Rights Agent a combined capital and surplus that is
similar or higher than the combined capital and surplus of the initial Rights Agent, or (b) an Affiliate of such Person. No Rights
Agent may be an Affiliate of the Company. After appointment, the successor Rights Agent shall be vested with the same powers, rights,
duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor
Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute
and deliver any further assurance, conveyance, act or deed necessary for the purpose; provided, that, the predecessor Rights Agent
shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. Not
later than the effective date of any such appointment the Company shall file notice thereof in writing with the predecessor Rights
Agent.

 

(c) The
Company shall give prompt notice to the Holders’ Representative of each resignation and each removal of a Rights Agent and
each appointment of a successor Rights Agent. Such notice shall include the name and address of the successor Rights Agent. If
the Company fails to send such notice within three (3) days after acceptance of appointment by a successor Rights Agent, the successor
Rights Agent shall cause such notice to be mailed at the expense of the Company.

 

Section 3.05. Acceptance
of Appointment by Successor.

 

Every successor Rights
Agent appointed hereunder shall execute, acknowledge and deliver to the Company, the Holders’ Representative and the retiring
Rights Agent (i) an instrument accepting such appointment and (ii) a counterpart of this Agreement, and thereupon such successor
Rights Agent, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of
the retiring Rights Agent; provided, that upon the request of the Company, the Holders’ Representative or the
successor Rights Agent, such retiring Rights Agent shall execute and deliver an instrument transferring to such successor Rights
Agent all the rights, powers and trusts of the retiring Rights Agent and shall cooperate in the transfer of all relevant data,
including the CVR Register, to the successor Rights Agent.

 

    - 13 -

     

    

 

ARTICLE
IV.

CERTAIN COVENANTS

 

Section 4.01. List
of Holders.

 

Wize shall furnish
or cause to be furnished to the Rights Agent (with a copy to the Holders’ Representative) (i) with respect to holders of
shares of Common Stock, in such form as Wize receives from its transfer agent (or other agent performing similar services for Wize),
and (ii) with respect to holders of shares of Common Stock, in such form as Wize receives from its transfer agent (or the names,
addresses and holdings of the Company’s holders of Common Stock as of the Record Date, within ten (10) Business Days after
the Effective Time.

 

Section 4.02. Performance
of Agreements.

 

Unless this Agreement
and the CVRs shall have been terminated as provided herein, from and after the date hereof, the Wize Subsidiaries, or, solely to
the extent applicable, Wize will use commercially reasonable efforts to perform all of its obligations under all LO2A Transaction
Agreements, if any. The parties hereto acknowledge that pursuant to the LO2A Transaction Agreements, third parties may be responsible
for, among other things, the development, regulatory filings, marketing and commercialization associated with the LO2A Technology.
Similarly, the Wize Subsidiaries will use commercially reasonable efforts to comply (or, where applicable, cause its subsidiaries
to comply) with the terms of the Resdevco Agreement and the BBG Exchange Agreement.

 

Section 4.03. Operations.

 

Subject to the terms
of this Agreement, including Section 4.04 below, neither Wize nor the Wize Subsidiaries has any obligation to operate the LO2A
Business in order to maximize any CVR Payment Amount; provided, that (A) the Wize Subsidiaries and Wize shall not, directly or
indirectly, take (or omit to take) any actions in bad faith or for the principal purpose of avoiding or reducing the amount of
CVR Payment Amounts payable under this Agreement or restricting their ability to pay the CVR Payment Amounts, and (B) for the sake
of clarity, Wize may not take, or commit to take, any of the following actions without the prior written consent of the Holders’
Representative or the Majority of CVR Holders (i) sell, transfer, encumber or otherwise dispose any shares of Wize US or any other
Wize Subsidiary, (ii) amend or modify the Resdevco Agreement, the BBG Exchange Agreement and/or the Acquisition Agreement, (iii)
use its voting rights in Wize US to affect the amount of any LO2A Consideration, or (iv) use its ownership or voting rights in
Wize US to circumvent or prevent Wize US from satisfying its obligations under this Agreement or the BBG Exchange Agreement.

 

Section 4.04. LO2A
Investment.

 

The Wize Subsidiaries
shall (and shall cause their Affiliates to) invest, at the request of the Holders’ Representative, in the development of
the LO2A Technology, including (i) by continuing the conduct of clinical trials, applying for regulatory approvals and engaging
advisors, and (ii) leasing space in Israel for such business, including all costs, capitalized costs and out of pocket expenses
in connection with the same (the “Post-Closing LO2A Investment”); it being understood and agreed that
any such Post-Closing LO2A Investment includes the license fees payable to Resdevco under the Resdevco Agreement.

 

Section 4.05 Books
and Records.

 

The Wize Subsidiaries,
and to the extent applicable, Wize shall make commercially reasonable efforts, and shall cause its subsidiaries to make commercially
reasonable efforts to, keep true, complete and accurate records in sufficient detail to enable the Holders’ Representative
and its representatives to determine the amounts payable hereunder.

 

    - 14 -

     

    

 

Section 4.05. Assignments.

 

Except as expressly
set forth in Sections 3.04 and 5.06, no party hereto may, in whole or in part, assign any of its rights or obligations under this
Agreement without the prior written consent of the other parties.

 

Section 4.06. Maximum
Post-Closing LO2A Investment and Transaction Expenses.

 

The Wize Subsidiaries
shall, at the request and direction of the Holders’ Representative, spend or incur up to US$300,000 of Post-Closing LO2A
Investment and any other Transaction Expenses; provided that, at the request of the Holders’ Representative, such amount
shall not be limited to US$300,000 if (i) the Holders’ Representative shall (or shall cause others to) finance or commit
to finance such excess on terms acceptable to Wize (not to be unreasonably withheld, provided that it shall be reasonable not to
accept any terms that include recourse against Wize, other than Permitted Liabilities), or (ii) in the event that an LO2A Transaction
Agreement is to be executed during the Transaction Term, to the extent that the proceeds payable under the LO2A Transaction Agreement
will likely cover such excess, such as in case of contingent fees payable to financial advisors (and, in which case, such excess
shall, for the sake of clarity, constitute Transaction Expenses), provided further that such amount is only incurred and not required
to be paid out of pocket until the completion of the LO2A Transaction.

 

Section 4.06. Reimbursement
of Transaction Expenses.

 

The Wize Subsidiaries,
and to the extent applicable, Wize, shall be reimbursed (or shall reimburse itself) for all Transaction Expenses incurred thereby
from the LO2A Consideration (or, in the case of the Post-Closing LO2A Investment of up to US$300,000, from its own resources);
provided, however, that the Wize Subsidiaries and, to the extent applicable, Wize shall provide the Holders’ Representative
with a report including all Transaction Expenses to be reimbursed or offset (with copies of invoices and reasonable explanation
of the nature of each expense).

 

ARTICLE
V.

THE HOLDERS’ REPRESENTATIVE

 

Section 5.01. Appointment
of Holders’ Representative.

 

By accepting CVRs,
the Holders hereby appoint, authorize and empower the Holders’ Representative to be the exclusive representative, agent and
attorney-in-fact of each Holder, with full power of substitution, to make all decisions and determinations and to act (or not act)
and execute, deliver and receive all agreements, documents, instruments and consents on behalf of and as agent for each Holder
at any time in connection with, and that may be necessary or appropriate to accomplish the intent and implement the provisions
of this Agreement and to facilitate the consummation of the transactions contemplated hereby, including without limitation for
purposes of (i) negotiating and settling, on behalf of the Holders, any dispute that arises under this Agreement after the Effective
Time, (ii) confirming the satisfaction of the Wize Subsidiaries’ and Wize’s obligations under this Agreement, (iii)
negotiating any LO2A Transaction and LO2A Transaction Agreement (including any LO2A Advisor Agreements), (iv) negotiating any Resdevco/BBG
Amendment, (v) negotiating and settling matters with respect to the amounts to be paid to the Holders pursuant to this Agreement,
(vi) decision regarding termination of the Resdevco Agreement, (vii) using any of its other powers and authorities contemplated
by this Agreement, including designation of directors to the boards of directors Wize Subsidiaries, and (viii) negotiating and
entering into any amendment, modification or waiver to this Agreement in accordance with Article VII hereof.

 

    - 15 -

     

    

 

Section 5.02. Authority.

 

The appointment of
the Holders’ Representative by the Holders pursuant to Section 5.01 is coupled with an interest and may not be revoked in
whole or in part (including, without limitation, upon the death or incapacity of any Holder). Subject to the prior qualifications,
such appointment shall be binding upon the heirs, executors, administrators, estates, personal representatives, officers, directors,
security holders, successors and assigns of each Holder. All decisions of the Holders’ Representative with respect to the
transactions contemplated hereby (including those actions covered under Section 5.01 above) shall be final and binding on all Holders.
Wize, the Wize Subsidiaries and the Rights Agent shall be entitled to rely upon, without independent investigation, any act, notice,
instruction or communication from the Holders’ Representative and any document executed by the Holders’ Representative
on behalf of any Holder and shall be fully protected in connection with any action or inaction taken or omitted to be taken in
reliance thereon. The Holders’ Representative shall not be responsible for any loss suffered by, or liability of any kind
to, the Holders arising out of any act done or omitted by the Holders’ Representative in connection with the acceptance or
administration of the Holders’ Representative’s duties hereunder, unless such act or omission involves gross negligence
or willful misconduct on the part of the Holders’ Representative; it being understood, including for purposes of Sections
5.03 and 5.04 below, that any decision or act of the Holders’ Representative that is approved by the Majority of CVR Holders
shall be prima facie evidence that the decision or act did not involve gross negligence or willful misconduct.

 

Section 5.03. Holders’
Representative Liability.

 

(a) The
Holders’ Representative shall be authorized and protected and shall not have any liability for, or in respect of any actions
taken, suffered or omitted to be taken by it in connection with this Agreement and the exercise and performance of its duties hereunder,
except to the extent such liability is a result of the willful misconduct or gross negligence of the Holders’ Representative
(each as determined by a final, non-appealable judgment of a court of competent jurisdiction). No provision of this Agreement shall
require the Holders’ Representative to expend or risk its own funds or otherwise incur any financial liability in the performance
of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or
adequate indemnification against such risk or liability is not reasonably assured to it.

 

(b) The
Holders’ Representative undertakes to perform such duties and only such duties as are specifically set forth in this Agreement,
and no implied duties, covenants or obligations shall be read into this Agreement against the Holders’ Representative.

 

(c) The
Holders’ Representative may rely and shall be authorized and protected in acting or refraining from acting upon any resolution,
certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, power of attorney, endorsement,
affidavit, letter or other paper or document believed by it to be genuine and to have been signed or presented by an officer of
the proper party or parties or upon any written instructions or statements from the Wize Subsidiaries, the Company or the Rights
Agent with respect to any matter relating to its acting as Holders’ Representative. The Holders’ Representative shall
not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder but as to which no notice
was provided, and the Holders’ Representative shall be fully protected and shall incur no liability for failing to take any
action in connection therewith unless and until it has received such notice.

 

(d) Whenever
the Holders’ Representative shall deem it necessary or desirable that any fact or matter be proved or established before
taking, suffering or omitting any action hereunder, the Holders’ Representative may request and rely upon an Officer’s
Certificate from the Company with respect to such fact or matter; and such certificate shall be full and complete authorization
and protection to the Holders’ Representative and the Holders’ Representative shall incur no liability for or in respect
of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate.
The Holders’ Representative shall be fully authorized and protected in relying upon the most recent instructions received
from the Company. In the event the Holders’ Representative believes any ambiguity or uncertainty exists hereunder or in any
notice, instruction, direction, request or other communication, paper or document received by the Holders’ Representative
hereunder, the Holders’ Representative, may, in its sole discretion, refrain from taking any action, and shall be fully protected
and shall not be liable in any way to the Company, the Wize Subsidiaries or any other Person for refraining from taking such action,
unless the Holders’ Representative receives written instructions from the Company that eliminates such ambiguity or uncertainty
to the satisfaction of the Holders’ Representative.

 

    - 16 -

     

    

 

(e) The
Holders’ Representative may engage and consult with counsel of its selection and the written advice of such counsel or any
opinion of counsel shall be full and complete authorization and protection to the Holders’ Representative in respect of any
action taken, suffered or omitted to be taken by it hereunder in reliance thereon in the absence of willful misconduct or gross
negligence on the part of the Holders’ Representative (as determined by a final, non-appealable judgment of a court of competent
jurisdiction).

 

(f) The
permissive rights of the Holders’ Representative to perform actions enumerated in this Agreement shall not be construed as
a duty.

 

(g) The
Holders’ Representative shall not be required to give any note or surety in respect of the execution of such powers or otherwise.

 

(h) The
Holders’ Representative shall not be liable for or by reason of any of the statements of fact or recitals contained in this
Agreement or be required to verify the same.

 

(i) The
Holders’ Representative shall not have any liability for or be under any responsibility in respect of the validity of this
Agreement or the execution and delivery hereof; nor shall it be responsible for any breach by the Wize Subsidiaries or the Company
of any covenant or failure by the Wize Subsidiaries or the Company to satisfy conditions contained in this Agreement.

 

(j) The
Holders’ Representative shall not be subject to, nor be required to comply with, or determine if any Person has complied
with any other agreement between or among any of the Company, the Wize Subsidiaries, or any other parties hereto (unless the Holders’
Representative is a party thereto), even though reference thereto may be made in this Agreement, or to comply with any notice,
instruction, direction, request or other communication, paper or document other than as expressly set forth in this Agreement.

 

(k) The
Holders’ Representative may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder
either itself or by or through its attorneys or agents, and the Holders’ Representative shall not be answerable or accountable
for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company, the Wize
Subsidiaries, the Holders, the Rights Agent or any other Person resulting from any such act, omission, default, neglect or misconduct,
absent gross negligence in the selection and continued employment thereof (which gross negligence must be determined by a final,
non-appealable judgment of a court of competent jurisdiction) and, in the event of arbitration or litigation in connection with
the matters contemplated herein, the Holders’ Representative may, but shall not be obligated to, engage and consult with
tax experts, valuation firms and other experts and third parties that it, in its sole and absolute discretion, deems appropriate
or necessary to enable it to discharge its duties hereunder.

 

(l) It
is acknowledged by each of the parties hereto that the Company and the Wize Subsidiaries have retained Goldfarb Seligman &
Co. (“Sellers’ Counsel”) to act as their counsel in connection with the transactions contemplated hereby
and that Sellers’ Counsel has not acted as counsel for any other Person in connection with the transactions contemplated
hereby and that no other party or Person has the status of a client of the Sellers’ Counsel for conflict of interest or any
other purposes as a result thereof.  The parties hereby agree that, in the event that a dispute arises between the parties
or any of their respective Affiliates and the Holders or the Holders’ Representative or any of its Affiliates, Sellers’
Counsel may represent the Holders and/or the Holders’ Representative in such dispute even though the interests of the Holders
or the Holders’ Representative may be directly adverse to the Company or any of its Affiliates and even though Sellers’
Counsel may have represented the Company or its Affiliates in a matter substantially related to such dispute, and the Company and
its Affiliates hereby waive, on behalf of themselves and each of their Affiliates, any conflict of interest in connection with
such representation by Sellers’ Counsel. Each of the parties further agrees that, as to all pre-Effective Time communications
among Sellers’ Counsel, any of the Company and its Affiliates, and any Holder or Holder’s Representative in the course
of the negotiation, documentation and consummation of the transactions contemplated by this Agreement, the attorney-client privilege,
the expectation of client confidence and all other rights to any evidentiary privilege belong to the Holders’ Representative,
and may be controlled by Holders’ Representative and shall not pass to or be claimed by Cosmos, the Company or any of their
respective Affiliates.  The parties agree to take, and to cause their respective Affiliates to take, all steps reasonably
necessary to implement the intent of this Section 5.03(l).

 

    - 17 -

     

    

 

Section 5.04. Indemnification

 

(a) Wize
agrees to indemnify and defend the Holders’ Representative (in this Section 5.04, including any of its family members, Affiliates,
directors, executive officers, shareholders, successors and assigns) for, and hold the Holders’ Representative harmless against,
any loss, liability, damage, judgment, fine, penalty, claim, demand, suit, settlement, cost or expense (including, without limitation,
the reasonable fees and out-of-pocket expenses of legal counsel), incurred without willful misconduct or gross negligence on the
part of the Holders’ Representative (the occurrence of each as determined by a final, non-appealable judgment of a court
of competent jurisdiction), for any action taken, suffered or omitted to be taken by the Holders’ Representative in connection
with the Holders’ Representative’s exercise or performance of its duties hereunder. For the avoidance of doubt, the
Holders’ Representative shall not be deemed to act in willful misconduct or gross negligence or in breach of this Agreement
if it acts in accordance with the written instructions received from the Majority CVR Holders (to the extent provided for herein)
or at the written advice of counsel.

 

(b) Promptly
(but in any event within seven (7) Business Days) after the receipt by the Holders’ Representative of written notice of any
demand or claim or the commencement of any action, suit, proceeding or investigation, the Holders’ Representative shall notify
the Company thereof in writing; provided, however, that any failure to do so in a timely manner shall not limit any of the
rights of the Holders’ Representative hereunder (except to the extent such failure materially prejudices the defense of such
demand). The Company shall be entitled to participate at its own expense in the defense of any such claim or proceeding, and, if
it so elects at any time after receipt of such notice, it may assume the defense of any suit brought to enforce any such claim
or of any other legal action or proceeding.

 

(c) For
the avoidance of doubt, it is hereby confirmed and agreed that the Company shall not settle any claim or proceeding in respect
of this Agreement for which the Holders’ Representative is not fully indemnified by the Company under this Agreement without
the prior written consent of the Holders’ Representative, which shall not be unreasonably withheld.

 

(d) For
the purposes of this Section 5.04, the terms “expense” or “loss” means any amount paid or payable to satisfy
any claim, demand, request, action, suit or proceeding settled with the written consent of the Holders’ Representative, and
all reasonable costs and expenses, including, but not limited to, counsel fees and disbursements, paid or incurred in investigating
or defending against any such claim, demand, action, suit, proceeding or investigation.

 

(e) The
provisions of Section 5.03 and this Section 5.04 shall survive the expiration of the CVRs, the termination of this Agreement, the
payment of any distributions made pursuant to this Agreement, and the resignation, replacement or removal of the Holders’
Representative hereunder.

 

Section 5.05. Holders’
Representative Fees and Expenses.

 

The Company agrees
to pay, or reimburse the Holders’ Representative promptly for, the Holders’ Representative’s out of pocket expenses
reasonably incurred in connection with this Agreement and the services the Holders’ Representative provides, including any
expense associated with exploring and negotiating any LO2A Transaction as well as all taxes and charges, reasonable out-of-pocket
expenses and other charges of any kind and nature, including reasonable fees and expenses of counsel to Holders’ Representative
(as well as the service fees agreed to below, as applicable) (“Holders’ Representative Fees and Expenses”).
In addition, and without derogating from the other provisions of this Section 5.05, upon the Successor Holders’ Representative
assuming the position of the Holders’ Representative, Holders’ Representative Fees and Expenses include reimbursement
of the Holders’ Representative for all taxes and charges, reasonable out-of-pocket expenses and other charges of any kind
and nature, including reasonable fees and expenses of the Holders’ Representative’s counsel and agent (other than taxes
measured by the Holders’ Representative’s income), paid or incurred by the Holders’ Representative in connection
with the discharging of the Holders’ Representative’s duties under this Agreement. The parties agree that the Company
(i) shall not pay the initial Holders’ Representative any fees for its services hereunder (other than, for the sake of clarity,
reimbursement of expenses as set forth above), and (ii) in case any Successor Holders’ Representative is appointed, it shall
pay a Successor Holders’ Representative a fee that shall not exceed the customary fees payable for such services at such
time.

 

    - 18 -

     

    

 

Section 5.06. Successor
Holders’ Representative.

 

(a)
The Holders’ Representative and any successor Holders’ Representative may resign and be discharged from its duties
under this Agreement at any time by giving written notice thereof to the Company, specifying a date when such resignation shall
take effect, which notice shall be sent at least 21 days before the date so specified.

 

(b) The
Holders’ Representative (and any successor thereof) may be removed for any reason or no reason by approval of a Majority
of CVR Holders, but only with the consent of Wize, which will not be unreasonably withheld.

 

(c) In
the event that the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder or resigns
or is removed from such position, a Majority of CVR Holders shall be authorized, with the consent of Wize, which will not be unreasonably
withheld, to and shall select another representative to fill such vacancy and such substituted representative shall be deemed to
be the Holders’ Representative for all purposes of this Agreement; provided however that if the initial Holders’
Representative named herein resigns, then the successor Holders’ Representative replacing the initial Holders’ Representative
named herein may be selected by the initial Holders’ Representative without approval of the Majority of CVR Holders.

 

(d) The
newly-appointed Holders’ Representative shall notify Wize and the Rights Agent in writing of his or her appointment, provide
evidence that a Majority of CVR Holders approved such appointment and provide appropriate contact information for purposes of this
Agreement. Wize, the Wize Subsidiaries and the Rights Agent shall be entitled to rely upon, without independent investigation,
the identity and validity of such newly-appointed Holders’ Representative as set forth in such written notice. In the event
that within 21 days after the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder
or resigns or is removed from such position and no successor Holders’ Representative has been so selected, Wize shall cause
the Rights Agent to notify the Person holding the largest quantity of the outstanding CVRs (and who is not Wize or any Affiliate
of Wize) that such Person is the successor Holders’ Representative, and such person shall be the successor Holders’
Representative hereunder. If such Person notifies the Rights Agent in writing that such Person declines to serve, the Rights Agent
shall forthwith notify the Person holding the next-largest quantity of the outstanding CVRs (and who is not Wize or any Affiliate
of Wize) that such next-largest-quantity Person is the successor Holders’ Representative, and such next-largest-quantity
Person shall be the successor Holders’ Representative hereunder. The Holders are intended third party beneficiaries of this
Section 5.06. If a successor Holders’ Representative is not appointed pursuant to the preceding procedure within sixty (60)
days after the Holders’ Representative dies, becomes unable to perform his or her responsibilities hereunder or resigns or
is removed from such position, Wize shall appoint a successor Holders’ Representative.

    - 19 -

     

    

 

ARTICLE
VI.

ADDITIONAL UNDERTAKINGS

 

Section 6.01. Availability
of Information.

 

The Company will
(i) subject to Section 8.14, provide to the Rights Agent and the Holders’ Representative (as the case may be), all information
in connection with this Agreement, the LO2A Transaction and the CVRs that such person may reasonably request, and (ii) in the case
of any LO2A Transaction, shall publish by way of a press release and/or Form 8-K, the key details thereof.

 

 Section 6.02. Consolidation,
Merger, Sale or Conveyance.

 

Without derogating
from the covenants set forth in Section 2.04 and Sections 4.02 to 4.04, in the event that the Wize Subsidiaries or the Company
shall consolidate with or merge into any other Person or convey, transfer or lease any or all of its properties and assets that
relate to LO2A Technology, the Wize Subsidiaries, or to the extent applicable, the Company shall cause the Person formed by such
consolidation or into which the Wize Subsidiaries, or to the extent applicable, the Company is merged or the Person that acquires
by conveyance or transfer, or that leases, such properties and assets of the Company (the “Surviving Person”)
to assume the obligations of the Wize Subsidiaries, or to the extent applicable, the Company under this Agreement and shall deliver
to the Rights Agent written confirmation of the Company and Person that the requirement of this Section 6.2 has been met. It is
hereby agreed, however, that if an LO2A Transaction involves the sale of the shares of (i) Wize US, then Wize US and Ocuwize shall
be automatically released from any and all of their rights and obligations hereunder, or (ii) OcuWize, then Ocuwize shall be automatically
released from any and all of its rights and obligations hereunder.

 

Section 6.03. Successor
Substituted.

 

Upon any consolidation
of or merger by the Wize Subsidiaries, or to the extent applicable, the Company with or into any other Person, or any conveyance,
transfer or lease of properties and assets in accordance with Section 6.02, the Surviving Person shall succeed to, and be substituted
for, and may exercise every right and power of, the Wize Subsidiaries, or to the extent applicable, the Company under this Agreement
with the same effect as if the Surviving Person had been named as the Wize Subsidiaries, or to the extent applicable, the Company
herein, and thereafter the predecessor Person shall be relieved of all obligations and covenants under this Agreement and the CVRs.

   

 

ARTICLE
VII.

AMENDMENTS

 

Section 7.01. Amendments
Without Consent.

 

(a)  Without
the consent of the Majority of CVR Holders or the Holders’ Representative, the Company, at any time and from time to time,
may enter into one or more amendments hereto, solely for the following purposes (provided that any amendment effected
prior to the Effective Time shall also require the written consent of Cosmos):

 

(i)   to
evidence the succession of another Person to the Wize Subsidiaries or the Company and the assumption by any such successor of the
covenants of the Company herein in a transaction contemplated by Section 6.02;

 

(ii) to
evidence the succession of another Person as a successor CVR Registrar and the assumption by any successor of the obligations of
the CVR Registrar herein;

 

(iii) to
evidence the succession of another Person as a successor Rights Agent and the assumption by any successor of the covenants and
obligations of the Rights Agent herein;

 

    - 20 -

     

    

 

(iv) as
may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange
Act; provided, that such provisions shall not adversely affect the interests of the Holders and/or to the interests
of the Holders’ Representative; or

 

(v) to
add to the covenants of the Company or the Wize Subsidiaries such further covenants, restrictions, conditions or provisions as
the Board shall consider to be for the protection of the Holders; provided, that in each case, such provisions shall
not adversely affect the interests of the Holders and/or to the interests of the Holders’ Representative.

 

(b) Any such amendment shall be fully valid even if such amendment is signed only by the Company and the Rights Agent.

 

(c) Promptly after
the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this Section 7.01, the Company
shall so notify the Holders’ Representative in writing.

 

Section 7.02. Amendments
with Consent.

 

(a) Subject
to Section 7.01 (which amendments pursuant to Section 7.01 may be made without the consent of
the Holders or the Holders’ Representative), with the written consent of the Holders’ Representative, and subject to
the receipt of the approval of a Majority of CVR Holders, the Company and the Rights Agent (and, prior to the Effective Time, Cosmos),
may enter into one or more amendments hereto (and, for the sake of clarity, the parties hereby agree that any amendment to the
Acquisition Agreement, if made following the Effective Time, shall be deemed as an amendment to this Agreement) for the purpose
of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is in any way
adverse to the interests of the Holders and/or to the interests of the Holders’ Representative. Any such amendment shall
be fully valid even if such amendment is signed only by the Company and the Rights Agent (and, prior to the Effective Time, Cosmos), provided, the
Holders’ Representative and a Majority of CVR Holders have consented thereto in writing. Notwithstanding the foregoing, the
approval of the Majority of CVR Holders shall not be required if (i) the amendment is approved by the written consent of the Holders’
Representative and (ii) such amendment, as approved by the Holders’ Representative, does not adversely effect the rights
of any Holder in any material respect and does not otherwise treat any Holder disproportionately and adversely in any respect from
all other Holders.

 

(b) Promptly
after the execution by the Company and the Rights Agent (and, prior to the Effective Time, Cosmos) of any amendment pursuant to
the provisions of this Section 7.02, the Company shall either (i) mail a notice thereof by first-class mail to the Holders at their
respective addresses as they shall appear on the CVR Register, setting forth in general terms the substance of such amendment,
or (ii) publish a notice thereof by way of a press release and/or filing a Form 8-K, setting forth in general terms the substance
of such amendment.

 

Section 7.03. Execution
of Amendments.

 

Before executing
any amendment permitted by this Article VII, the Rights Agent shall be entitled to receive, and shall be fully protected in relying
upon, an opinion of counsel stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights
Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent’s own rights, privileges,
covenants, immunities, obligations or duties under this Agreement or otherwise. No supplement or amendment to this Agreement shall
be effective unless duly executed by the Rights Agent.

 

Section 7.04. Effect
of Amendments.

 

Upon the execution
of any amendment under this Article VII, this Agreement shall be modified in accordance therewith, such amendment shall form a
part of this Agreement for all purposes and the Holders’ Representative and to the extent valid and binding under applicable
law every Holder shall be bound thereby.

 

    - 21 -

     

    

 

ARTICLE
VIII.

OTHER PROVISIONS OF GENERAL APPLICATION

 

Section 8.01. Termination.

 

This Agreement and
all CVRs shall terminate automatically and without any action on the part of the Company, the Wize Subsidiaries, any Holder, the
Holders’ Representative, the Rights Agent or any other Person on the earlier of (i) the Program Termination Date; (ii) 180
days following the Last CVR Entitlement Date (as such period may be extended, in the event of the delivery of a Notice of Objection,
until the final determination thereof in accordance with this Agreement, including, if applicable, the fulfillment of any payment
or other obligation required pursuant to such final determination); and (iii) if the Acquisition Agreement is validly terminated
in accordance with its terms following the date hereof (such earlier date, the “Termination Date”), and
neither this Agreement nor any CVR shall be of any force or effect thereafter, and the Company shall have no liability hereunder
or thereunder, other than with respect to (i) the Wize Subsidiaries, or to the extent applicable, the Company’s obligation
to pay any CVR Payment Amount due and owing to the Holders in accordance with the terms of this Agreement as of the Termination
Date; (ii) the Company’s obligation to pay any amount due and owing by the Company to the Rights Agent or the Holders’
Representative under this Agreement as of the Termination Date); (iii) any obligation or liability arising from any prior
breach by the Wize Subsidiaries, or to the extent applicable, the Company of any provision of this Agreement; provided that
Sections 3.03(g), 3.03(h), 5.03, 5.04, and this Article VIII shall survive any termination or expiration of this Agreement and
shall remain fully effective and enforceable thereafter.

 

Section 8.02. Notices
to the Rights Agent, the Company, Cosmos and/or the Holders’ Representative.

 

Any request, demand,
authorization, direction, notice, consent, waiver or other document provided or permitted by this Agreement to the Rights Agent,
the Company, the Wize Subsidiaries, Cosmos and/or the Holders’ Representative shall be sufficient for every purpose hereunder
if in writing and delivered personally, sent by email, sent by certified or registered mail (return receipt requested), sent by
first-class mail, postage prepaid or sent by a nationally recognized overnight courier (with proof of service), addressed as set
forth in Schedule 2, and shall be deemed to have been given upon receipt (with confirmation of receipt, if by email).

 

Section 8.03. Notice
to Holders.

 

Where this Agreement
provides for notice to Holders, such notice shall be sufficiently given (unless otherwise herein expressly provided) if in writing
and mailed, first-class postage prepaid, to each Holder affected by such event, at his, her or its address as it appears in the
CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the giving of such notice.
In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so
mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders.

 

Section 8.04. Effect
of Headings.

 

The Article and Section
headings herein are for convenience only and shall not affect the construction hereof.

 

Section 8.05. Benefits
of Agreement.

 

Nothing in this Agreement,
express or implied, shall give to any Person (other than the parties hereto, the Holders and their permitted successors and permitted
assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision
herein contained, all such covenants and provisions being for the sole benefit of the parties hereto, the Holders and their permitted
successors and permitted assigns; provided, that the Holders shall have no rights or remedies hereunder except as expressly
set forth herein.

 

    - 22 -

     

    

 

Section 8.06. Governing
Law; Jurisdiction.

 

(a) This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any
choice or conflict of law principals, whether of the State of Delaware or any other jurisdiction, that would cause the application
of the laws of any jurisdiction other than the laws of the State of Delaware. In any action or suit among any of the Company, the
Wize Subsidiaries, Cosmos, the Rights Agent, the Holders’ Representative and the Holders arising out of or relating to this
Agreement: (a) each of the Company, the Wize Subsidiaries, the Rights Agent, the Holders’ Representative and, to the extent
valid and binding under applicable law, Holders irrevocably and unconditionally consents and submits to the exclusive jurisdiction
and venue of the state and federal courts located in the State of Delaware; (b) if any such action or suit is commenced in such
state court, then, none of the Company, the Wize Subsidiaries, the Rights Agent, Cosmos, the Holders’ Representative and,
to the extent valid and binding under applicable law, the Holders shall object to the removal of such action or suit to any federal
court located in the District of Delaware; and (c) each of the Company, the Wize Subsidiaries, the Rights Agent, Cosmos, the Holders’
Representative or, to the extent valid and binding under applicable law, the Holders irrevocably waives the right to trial by jury.

 

(b) EACH
PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY SUIT, ACTION OR OTHER PROCEEDING, DIRECTLY OR INDIRECTLY, ARISING OUT OF, UNDER OR RELATING TO THIS AGREEMENT. EACH PARTY
HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT,
IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE
OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS
IN THIS SECTION 8.06(b) .

 

Section 8.07. Legal
Holidays.

 

In the event that
a CVR Payment Date shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary, any payment
required to be made in respect of the CVRs on such date need not be made on such date, but may be made on the next succeeding Business
Day with the same force and effect as if made on the CVR Payment Date.

 

Section 8.08. Fund.

 

All funds received
by the Rights Agent under this Agreement that are to be distributed or applied by the Rights Agent in the performance of the services
contemplated hereunder (the “Funds”) shall be held by the Rights Agent as agent for the Holders and the
Wize Subsidiaries, or to the extent applicable, the Company deposited in one or more bank accounts to be maintained by the Rights
Agent in its name as agent for the Holders and the Wize Subsidiaries, or to the extent applicable, the Company. Until paid pursuant
to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts of (i) Citi Bank
or (ii) other commercial banks with Tier 1 capital exceeding $1 billion or with an average rating above investment grade by S&P
(LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported
by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution of the Funds, including
any losses resulting from a default by any bank, financial institution or other third party, that may result from any deposit made
by the Rights Agent in accordance with this paragraph. The Rights Agent may from time to time receive interest, dividends or other
earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest, dividends or earnings
to the Company, the Wize Subsidiaries, any Holder or any other party.

 

    - 23 -

     

    

  

Section 8.09. Severability
Clause.

 

Any term or provision
of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in
any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term
or provision of this Agreement is invalid or unenforceable, the Company, the Wize Subsidiaries, the Holders’ Representative,
the Rights Agent and, prior to the Effective Time, Cosmos, agree that the court making such determination will have the power to
limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision
that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision,
and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to
it in the preceding sentence, the Company, the Wize Subsidiaries, the Holders’ Representative, the Rights Agent and, prior
to the Effective Time, Cosmos agree to replace such invalid or unenforceable term or provision with a valid and enforceable term
or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term or provision; provided, however, that if such term or provision, whether modified by the court or the agreement of
the or the other parties hereto, shall adversely affect the rights, immunities, liabilities, duties or obligations of the Rights
Agent (in its sole discretion), the Rights Agent shall be entitled to resign immediately upon written notice to the Company and
the Holders’ Representative.

 

Section 8.10. Counterparts.

 

This Agreement may
be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same
instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties hereto by electronic transmission,
including in PDF format, shall be sufficient to bind the parties to the terms and conditions of this Agreement.

 

Section 8.11. Entire
Agreement.

 

As it relates to
the Rights Agent, this Agreement and the schedules and exhibits attached hereto represents the entire understanding of the parties
hereto regarding the CVRs and the other transactions contemplated hereby, and this Agreement supersedes any and all other oral
or written agreements made with respect to the CVRs. As it relates to the Company, the Wize Subsidiaries, Cosmos, the Holders’
Representative and the Holders, this Agreement represents the entire understanding of the Company, the Wize Subsidiaries, Cosmos,
the Holders’ Representative and the Holders, regarding the CVRs and the other transactions contemplated hereby, and this
Agreement supersedes any and all other oral or written agreements made with respect to the CVRs. If and to the extent that any
provision of this Agreement is inconsistent or conflicts with the Acquisition Agreement, this Agreement shall govern and be controlling.

 

Section 8.12. Other
Remedies; Specific Performance.

 

Except as otherwise
provided herein, any and all remedies herein expressly conferred upon the Company, the Wize Subsidiaries, the Rights Agent, the
Holders’ Representative, Cosmos and the Holders will be deemed cumulative with and not exclusive of any other remedy conferred
hereby, or by law or equity upon any of them, and the exercise by the Company, the Wize Subsidiaries, the Rights Agent, the Holders’
Representative, Cosmos or the Holders of any one remedy will not preclude the exercise of any other remedy. The Company, the Wize
Subsidiaries, the Holders’ Representative, Cosmos and the Holders agree that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the Company, the Wize Subsidiaries, the Holders’ Representative, Cosmos and the Holders (acting
through the Holders’ Representative or by consent of the Majority of CVR Holders) shall be entitled to an injunction or injunctions
to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States,
the State of Israel or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at
law or in equity, and each of the Company, the Wize Subsidiaries, the Holders’ Representative, Cosmos and the Holders waives
any bond, surety or other security that might be required of any other with respect thereto.

 

    - 24 -

     

    

 

Section 8.13. 
No Fiduciary Obligations.

 

Each party acknowledges
and agrees (and the Holders are deemed to agree) that the Holders’ Representative does not owe any fiduciary duties to either
party or any of the Holders.

 

Section 8.14. 
Confidentiality.

 

The parties hereto
agree that all books, records, information and data pertaining to the business of the Rights Agent, including inter alia,
personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this
Agreement including the fees for services provided hereunder shall remain confidential, and shall not be voluntarily disclosed
to any other person, except (i) as may be required by law, including, without limitation, pursuant to subpoenas from state or federal
government authorities (e.g., in divorce and criminal actions), (ii) as may be required by the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, in each case including the rules and regulations promulgated thereunder, (iii)
as may be required by the rules and regulations of any national securities exchange or over the counter market on which any of
the Company’s securities are then listed or admitted for trading or (iv) with the prior written consent of the Rights Agent
(not to be unreasonably withheld).

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    - 25 -

     

    

 

IN WITNESS
WHEREOF, each of the parties has caused this Contingent Value Rights Agreement to be executed on its behalf by its duly authorized
officers as of the day and year first above written. 

 

	WIZE PHARMA, INC. 	 	Cosmos Capital Limited
	 	 	 
	By:	            	 	By:	           
	Name: 	 	 	Name: 	 
	Title:		 	Title:	 

 

	
        [●],
as Rights Agent

	 
	By:	     	 
	Name: 		 
	Title:  	 	 

  

	[●], as Holders’ Representative	 
	 	 	 
	By:	                  	 
	Name: 	 	 
	Title:	 	 

 

	Wize [   ], Inc.	 
	 	 	 
	By: 	      	 
	Name: 		 
	Title:	 	 
	 	 	 
	OcuWize Ltd.	 
	 	 	 
	By: 	     	 
	Name: 		 
	Title:	 	 

 

    - 26 -

     

    

 

Schedule
1

 

Rights
Agent Fees and Expenses

 

[Omitted. The registrant
agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission upon request.]

 

 

 

    - 27 -

     

    

 

Schedule
2

 

Address
for Notices

 

[Omitted. The registrant
agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission upon request.]

 

 

 

    - 28 -

     

    

 

Schedule
3

 

Authorized
Representatives 

 

[Omitted. The registrant
agrees to furnish supplementally a copy of such omitted appendix to the U.S. Securities and Exchange Commission upon request.]

 

 

 

 

 

- 29 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]